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Abstract
Long-term mechanical circulatory support (LT-MCS) is an important treatment modality for patients with severe heart failure. Different
devices are available, and many—sometimes contradictory—observations regarding patient selection, surgical techniques, perioperative
management and follow-up have been published. With the growing expertise in this field, the European Association for Cardio-Thoracic
Surgery (EACTS) recognized a need for a structured multidisciplinary consensus about the approach to patients with LT-MCS. However,
the evidence published so far is insufficient to allow for generation of meaningful guidelines complying with EACTS requirements. Instead,
the EACTS presents an expert opinion in the LT-MCS field. This expert opinion addresses patient evaluation and preoperative optimization
as well as management of cardiac and non-cardiac comorbidities. Further, extensive operative implantation techniques are summarized
and evaluated by leading experts, depending on both patient characteristics and device selection. The faculty recognized that postopera-
tive management is multidisciplinary and includes aspects of intensive care unit stay, rehabilitation, ambulatory care, myocardial recovery
and end-of-life care and mirrored this fact in this paper. Additionally, the opinions of experts on diagnosis and management of adverse
events including bleeding, cerebrovascular accidents and device malfunction are presented. In this expert consensus, the evidence for the
complete management from patient selection to end-of-life care is carefully reviewed with the aim of guiding clinicians in optimizing man-
agement of patients considered for or supported by an LT-MCS device.
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1. ABBREVIATIONS AND ACRONYMS
AR Aortic regurgitation
BiVAD Biventricular assist device
BSI Bloodstream infection
CC Cardiac cachexia
CF Continuous-flow
CHD Congenital heart disease
CPB Cardiopulmonary bypass
EACTS European Association for Cardio-Thoracic Surgery
EOL End of life
EUROMACS European Registry for Patients with Mechanical
Circulatory Support
GI Gastrointestinal
HF Heart failure
HTx Heart transplant
ICD Implantable cardioverter defibrillator
iNO Inhaled nitric oxide
INTERMACS Interagency Registry for Mechanically Assisted
Circulatory Support
INR International normalized ratio
LT-MCS Long-term mechanical circulatory support
LV Left ventricle
LVAD Left ventricular assist device
MCS Mechanical circulatory support
PC Palliative care
PVR Pulmonary vascular resistance
RD Renal dysfunction
RM Remote monitoring
RV Right ventricle
RVAD Right ventricular assist device
TAH Total artificial heart
TOE Transoesophageal echocardiography
VA Ventricular arrhythmia
VAD Ventricular assist device
2. INTRODUCTION
Long-term durable mechanical circulatory support (LT-MCS) has
evolved significantly in the last decade. Today’s devices have become
more reliable, and their durability has increased whereas device-
related complications have drastically decreased compared with ear-
lier generations of devices. In addition to a growing population with
end-stage heart failure (HF), these developments have led to a nota-
ble increase in MCS implants, particularly of continuous-flow left
ventricular assist devices (CF-LVADs). In Germany only, nearly 1000
LVADs were implanted in 2016 [1]. Thus, LT-MCS has become a
standard of care in the treatment of end-stage HF. Moreover, the
availability of smaller blood pumps together with growing clinical
experience has expanded the target population by extending LT-
MCS to patients with more complex conditions, including elderly
and paediatric patients, patients with congenital heart defects and
patients with advanced comorbidities. This expansion has resulted in
a significant increase in the complexity of all aspects of management
of these patients from selection to postoperative management, which
is recognized in the presented consensus statement.
The European Association for Cardio-Thoracic Surgery
(EACTS) has not recently provided guidance on LT-MCS.
However, since the available scientific evidence consists mainly
of observational studies with a few randomized clinical trials, it
would not be feasible to formulate a full set of guidelines that
meets EACTS criteria. Therefore, the EACTS provides an expert
consensus statement in this document.
In this statement, we have generally refrained from using the
designations of bridge to transplant and destination therapy in
accordance with the more recent randomized trials in this field
[2a]. This decision relates to the fact that, although a cardiac trans-
plant is intended in the majority of LT-MCS recipients, only a
minority will ever receive a donor organ in Europe. In a recent
report of the ELEVATE (Evaluating the HeartMate 3 with Full
MagLev Technology in a Post-Market Approval Setting) registry of
more than 450 consecutive patients (mainly European) under-
going implantation of LT-MCS, only 2% received a transplant after
1 year, despite 26% of the patients receiving an implant as a desti-
nation therapy strategy [2b]. The latter also underscores the need
for guidance of long-term management of MCS recipients, which
consequently is an integral part of this statement.
As is stated in the present expert consensus, the multidiscipli-
nary team of surgeons, intensive care specialists, cardiologists,
perfusionists, LT-MCS coordinators, psychologists and other
allied health care professionals should be involved in all stages of
treatment of patients with LT-MCS. This goal is evident in the
present expert consensus, which includes authors drawn from all
the different specialties involved in the care of the patients with
MCS. Furthermore, the chapters focusing on surgical aspects are
complemented by chapters on medical management including
patient selection, preoperative optimization, intensive care,
ambulatory care and, finally, palliative care (PC).
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3. METHODS
A task force of experts from cardiac surgery, cardiology, cardiac
anaesthesiology and intensive care was assembled by the EACTS
to formulate this expert consensus. The topic for the consensus
was decided by the EACTS leadership. The task force members
met to discuss all recommendations in a plenary session and uti-
lized standard recommendation and evidence level nomencla-
ture as described below (Tables 1 and 2).
A literature search was performed by the authors of the vari-
ous chapters and an overall complementary literature search was
performed by a member of the task force (C.A.).
4. PATIENT EVALUATION AND TIMING OF
IMPLANTATION
4.1 Background
Patient evaluation and selection for LT-MCS as a therapy for
advanced HF involves consideration of multiple factors. LT-MCS is
associated with early and late risks of adverse events [3],
substantial resource utilization and costs [4, 5], hospital readmis-
sions [6] and the potential for considerable suffering for patients
and families [7]. It is therefore crucial that patient selection
achieves the greatest treatment effect possible by targeting
patients with the highest benefit/risk ratio [8]. Current HF guide-
lines of the European Society of Cardiology [9] recommend the
use of LT-MCS; however, selection criteria for evaluation of poten-
tial candidates are lacking. Nonetheless, extensive data are avail-
able that predict outcomes with and in the absence of LT-MCS.
4.2 Evidence review
Major trials have established the efficacy of LVADs in patients
with a low left ventricular ejection fraction (<_25%), who were ino-
trope dependent or were persistently New York Heart
Association (NYHA) functional class IIIb or IV despite optimal
medical therapy. Additionally, a maximal oxygen consumption
below 12 ml/kg/min was often used as an inclusion criterion.
4.3 Levels of the Interagency Registry for
Mechanically Assisted Circulatory Support
The Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) and the European Registry for Patients
with Mechanical Circulatory Support (EUROMACS) stratify
patients with advanced HF into 7 levels that are useful for guid-
ing patient evaluation (Supplementary Material, Table S1) [10]. A
majority of patients included in LT-MCS trials had INTERMACS
levels 1–4. Outcomes with LT-MCS in INTERMACS level 1 are
poorer than those in levels 2–3 and bridging with temporary
MCS in the former is recommended [11, 12].
4.4 Biventricular failure
Patients with chronic biventricular failure with severe right ventric-
ular failure are not good candidates for LT-MCS with LVAD ther-
apy alone. Biventricular support with 2 blood pumps (implantable
or extracorporeal) or implantation of a total artificial heart (TAH)
should be considered. However, patients presenting with acute
biventricular failure could initially be treated with a biventricular
assist device (BiVAD) and may ultimately prove to be candidates
for LVAD support only after a period of right ventricle (RV)
unloading with a temporary right ventricular assist device (RVAD).
Due to the limitations of any single criterion to predict HF prog-
nosis and MCS postoperative mortality, comprehensive risk assess-
ment by a dedicated advanced HF team is recommended.
Numerous single risk markers and composite risk scores have
been derived and validated and are available as interactive online
tools that can assist the heart team with comprehensive risk
assessments and facilitate informed decisions (Supplementary
Material, Table S2) [13–16]. However, most of the prognostic tools
were derived and validated in clinical trial populations or from
single-centre experiences. Therefore, these may not be generaliz-
able to the ‘real-world’ HF population.
Nevertheless, objective risk markers and scores, if deployed as
part of a comprehensive assessment by an HF team, are useful for
prognostication and prioritization [17]. Clinical history such as
recurrent HF hospitalizations and the physician’s gestalt from the
patient encounter are critical. Moreover, numerous plasma bio-
markers of neurohormonal activation, cardiomyocyte injury or
Table 2: Levels of evidence
Table 1: Classes of recommendations
Classes of
recommendations
Definition Suggested wording to use
Class I Evidence and/or general agreement 
that a given treatment or procedure is
beneficial, useful, effective.
Is recommended/is 
indicated
Class II Conflicting evidence and/or a 
divergence of opinion about the 
usefulness/efficacy of the given 
treatment or procedure.
Class IIa Weight of evidence/opinion is in favour 
of usefulness/efficacy.
Should be considered
Class IIb Usefulness/efficacy is less well 
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure is 
not useful/effective, and in some cases
may be harmful. 
Is not recommended
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stress, inflammation, fibrosis and multifactorial markers are inde-
pendent markers of outcome in patients with advanced HF [18].
The cardiopulmonary exercise test provides a set of integrated
parameters that represent not only cardiac but also peripheral
function. This finding may be particularly helpful in selecting
patients who are not inotrope-dependent for LT-MCS therapy,
given the fact that impaired exercise tolerance was an inclusion cri-
terion in most LT-MCS studies.
It is crucial to perform a thorough evaluation of the psycho-
social situation of potential candidates for LT-MCS. For exam-
ple, outcomes after LT-MCS implantation are inferior
in patients living alone [19]. Active substance abuse is a contra-
indication to implantation of LT-MCS. Finally, non-patient-
related factors, such as organization of care and access to
follow-up and treatment, are also strongly associated with out-
comes [20].
Recommendations for evaluation and selection of patients for LT-MCS therapy
Recommendation Class Level References
It is recommended that reversible causes of heart failure are ruled out. I B
LT-MCS implantation should be considered in patients with the following:
• New York Heart Association functional class IIIB–IV and
• Ejection fraction <_25% and
At least one of the following criteria:
 INTERMACS 2–4
 Inotrope dependence
 Progressive end-organ dysfunction
 Peak VO2 <12 ml/kg/min
 Temporary MCS dependence
IIa B
LT-MCS implantation may be considered in patients with:
• New York Heart Association functional class IIIB–IV and
• Ejection fraction <_25% and
 To reverse elevated pulmonary vascular resistance or potentially reversible renal failure in potential
heart transplant candidates
 To allow time for transplant contraindications to be reversed such as recent cancer, obesity and
recovering drug and alcohol dependence in potential heart transplant candidates
IIb B
Patient characteristics associated with a high risk of poor outcome post-left ventricular assist device
LT-MCS in patients with advanced age, after careful evaluation of comorbidities and frailty, should be
considered.
IIa C [3, 22–25]
LT-MCS in patients with peripheral vascular disease, depending on its severity, may be considered. IIb C
LT-MCS in patients with active systemic bacterial/fungal infection is not recommended. III B [26, 27]
In patients with well controlled HIV, hepatitis B or hepatitis C, LT-MCS should be considered. IIa B [26, 27]
In patients with diabetes with poor glycaemic control or end-organ complications, LT-MCS may still be
considered.
IIb B [22, 28–30]
LT-MCS may be considered in patients with chronic dialysis. IIb C [31–34]
LT-MCS implantation in patients with haemostatic deficiencies and coagulopathies may be considered. IIb B [35–38]
LT-MCS implantation in patients with untreated aortic regurgitation or mechanical aortic valve is not
recommended.
III C [39, 40]
LT-MCS in patients with untreated severe mitral stenosis is not recommended. III C
LT-MCS implantation in patients with irreversible liver dysfunction, as diagnosed by liver enzyme laboratory
tests and the Model of End-stage Liver Disease score, is generally not recommended.
III B [41]
In patients with poor neurological and cognitive function, LT-MCS implantation is not recommended. III B [42, 43]
Frail patients and patients with limited mobility may, after careful evaluation, be considered for LT-MCS
implantation.
IIb B [44–48]
LT-MCS in patients who are living alone or who are suffering from depression should, after careful
evaluation, be considered.
IIa C [19, 49–53]
LT-MCS implantation in patients who suffer from dementia is not recommended. III C [19, 49–53]
LT-MCS implantation in patients with active substance abuse, not willing to cease the abuse, is not
recommended.
III C
LT-MCS implantation in patients with malignancies may be considered if expected survival is >1 year. IIb C [33]
HIV: human immunodeficiency virus; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; LT-MCS: long-term mechanical circulatory
support.
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Despite the availability of an extensive set of prognostic
parameters, predicting outcomes both in the absence and
presence of advanced HF interventions remains difficult.
Furthermore, patients are often referred to specialized
advanced HF centres too late. The concept of active screening
for advanced intervention has been proposed to improve
appropriate referral and treatment in patients with advanced
HF [21].
5. PREOPERATIVE ORGAN FUNCTION
OPTIMIZATION
In the context of HF, end-organ dysfunction is a hallmark of very
advanced disease and is associated with increased risk of early
death. Prior to surgery, a comprehensive patient evaluation to
identify pre-existing comorbid conditions that may influence
postoperative survival that could be optimized preoperatively is
recommended [33].
Optimization plays a fundamental role in patients with
INTERMACS levels 3–4 because there is more time for planning
the implant [54, 55]. Preoperative optimization is in continuous
interplay with haemodynamics, because low cardiac output and
RV failure or fluid overload are key targets of treatment. In these
perspectives, their potential for improvement and timing are piv-
otal. Indeed, the interaction between the RV and end-organ
function is to be acknowledged because the latter is a risk factor
for RV failure. At baseline, organ function should be routinely
assessed with standard parameters; therefore, haemodynamic
evaluation and the potential for its management with a tailored
pharmacological or short-term MCS device should follow.
Optimization does not mean normalization; a positive trend fol-
lowing specific treatment is to be taken as a goal. Similarly, no
conclusion about reversibility of organ dysfunction can be drawn
until cardiac output and filling pressures have been optimized.
As a general rule, recent onset HF and young age may be associ-
ated with a higher probability of recovery of end-organ dysfunc-
tion if cardiac output is restored.
Recommendations for preoperative organ function optimization
Recommendation Class Level References
Renal function
In patients with renal dysfunction, optimization via improvement of cardiac output and reduction of filling
pressures is recommended.
I B [56]
Liver function
Liver function evaluation with bilirubin is recommended. I B [57, 58]
In patients with increasingly elevated bilirubin levels, temporary MCS, ahead of possible LT-MCS implanta-
tion, may be considered.
IIb B [59]
Pulmonary function
Treatment of preimplant pulmonary oedema is recommended before implantation. I B [60, 61]
Left ventricular unloading on extracorporeal life support to optimize lung function should be considered. IIa B [62]
Respiratory physiotherapy should be considered. IIa C
Coagulation
Withdrawal of dual antiplatelet therapy and/or vitamin K antagonists to reduce the risk of bleeding is
recommended.
I B [63, 64]
The use of short-acting intravenous anticoagulation as bridging is recommended. I B [64]
Administration of procoagulants shortly before implantation of the LT-MCS may be considered. IIb B [64]
Optimization of coagulation prior to surgery should be considered, especially in patients on temporary MCS. IIa C
Nutritional, metabolic and endocrine considerations
Preoperative assessment of metabolic, endocrine and nutritional status, including possible interventions for aris-
ing issues, should be considered.
IIa C
Nutritional support, if necessary, may be considered. IIb C [65, 66]
LT-MCS: long-term mechanical circulatory support.
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6. CONCOMITANT CARDIAC CONDITIONS
INCLUDING ARRHYTHMIAS
6.1 Background
To increase survival and to reduce the complication rates after
the operation, preoperative evaluation and identification of
other cardiac conditions are of utmost importance. Presence of
concomitant cardiac diseases requires appropriate intraoperative
planning [33, 67]. Although it is clear that mechanical valves in
the aortic position must be replaced by a bioprosthetic valve
prior to implantation of an LVAD or BiVAD, there is accumulat-
ing experience with leaving mechanical mitral valves in situ.
Clearly, more data in this area are needed before firm recom-
mendations regarding the requirement to replace the mechani-
cal mitral valve can be made.
Recommendations for concomitant cardiac condition including arrhythmias
Recommendation Class Level References
Aortic valve and root diseases
Biological valve replacement in patients with more than mild aortic insufficiency should be considered. IIa B [68, 69]
Application of a central leaflet coaptation stitch may be considered in patients with more than mild aortic
insufficiency.
IIb B [68–70]
Closure of aortic valve in patients with more than mild aortic insufficiency is not recommended. III C [68, 69]
It is recommended that a functional bioprosthesis be left in place. I C [69, 71]
Replacement of a mechanical aortic valve with a biological valve is recommended. I C [69, 71]
Closure of mechanical aortic valves is not recommended. III C [68, 69]
Surgical correction of an ascending aorta aneurysm at the time of implantation of a ventricular assist device
should be considered.
IIa C [70]
Mitral valve disease
Correction of moderate or severe mitral stenosis of any cause (including transcatheter interventions) is
recommended.
I C [71, 72]
In selected patients, the repair of severe mitral insufficiency may be considered. IIb C [73–75]
Exchange of a functional mitral mechanical or biological prosthesis at the time of long-term mechanical
circulatory support device implantation is not recommended.
III C [71]
In patients previously treated with a MitraClip, a thorough evaluation to rule out the existence of mitral valve
stenosis is recommended.
I C
Tricuspid valve disease and right ventricular dysfunction
Correction of severe tricuspid stenosis at the time of long-term mechanical circulatory support implantation is
recommended.
I C
Re-evaluation of patients with moderate to severe tricuspid regurgitation after treatment with diuretic therapy,
if condition permits, is recommended.
I C [76]
In carefully selected patients, tricuspid valve repair for moderate to severe tricuspid regurgitation at the time of
long-term mechanical circulatory support implantation may be considered.
IIb C [77–80]
Implantation of a biventricular assist device or a total artificial heart in patients with severe tricuspid regurgitation
and right ventricular dysfunction may be considered.
IIb C [81]
Intracardiac shunts
Closure of a patent foramen ovale, either percutaneously or at the time of LT-MCS implantation, is
recommended.
I C [71]
Depending on the shunt volume, closure of an iatrogenic atrial septal defect after trans-septal intervention is
recommended.
I C
Intensive use of transoesophageal echocardiography in the operating room directly after LT-MCS implantation
is recommended.
I C [71, 72]
Closure of a ventricular septal defect during LT-MCS implantation is recommended. I C
In patients with an unrepairable ventricular septal defect, LT-MCS implantation is not recommended. III C [71]
Continued
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7. MANAGEMENT OF NON-CARDIAC
COMORBIDITIES
7.1 Background
At the time of LT-MCS implantation, patients are usually in their
mid-50s (EUROMACS: mean 51.7, median 55 years) [91] or older
(International Society for Heart and Lung Transplantation
Mechanically Assisted Circulatory Support Registry, second report:
72% at >50 years) [92]. The majority of candidates for LT-MCS are
INTERMACS level 3 or less, meaning at least they are inotrope
dependent. Advanced age and inotrope dependency are both
associated with comorbidities. Therefore, a thorough preimplant
examination is crucial to identify absolute contraindications for
LT-MCS implantation such as surgical contraindications, severe
coagulation and haematological disorders and irreversible multi-
organ failure. Moreover, life-limiting comorbidities and the chance
of improvement after LT-MCS implantation can be assessed.
7.2 Evidence review
Malignancies are often the reason to choose a bridge-to-
candidacy strategy [93].
Frailty is a biological syndrome of impaired physiological and
homeostatic reserve and heightened vulnerability to stressors,
resulting from multiple morbidities, ageing and disability [94],
occurring in nearly 10% of the patients in the INTERMACS Registry
[95]. Frailty contains at least one of the following phenotype symp-
toms: shrinking, weakness, exhaustion, slowness and inactivity. No
Arrhythmia
Medical or surgical intervention (according to European Society of Cardiology/European Heart Rhythm
Association, Heart Rhythm Society Guidelines) for atrial tachyarrhythmia is recommended.
I C [79, 82, 83]
Routine implantation of an implantable ICD for primary prophylaxis before long-term mechanical circulatory
support implantation is not recommended.
III C [84]
In patients with an ICD, preoperative evaluation of a possible ventricular assist device–ICD interaction may be
considered.
IIb C [85]
Concomitant VT ablation during long-term mechanical circulatory support device implantation in patients with
a history of frequent VTs may be considered.
IIb C [86, 87]
In patients with refractory, recurrent VT/ventricular fibrillation in the presence of an untreatable
arrhythmogenic substrate (e.g. giant cell myocarditis or sarcoidosis), implantation of a biventricular assist
device or a total artificial heart should be considered.
IIa C
Intracardiac thrombus
Echocardiography, computed tomography or magnetic resonance imaging in patients suspected of having an
intracardiac thrombus is recommended.
I C [71]
In patients with atrial fibrillation, due to the increased risk of thromboembolism from the LAA,
a transoesophageal echocardiogram should be considered.
IIa C [72]
In patients with atrial fibrillation, LAA closure may be considered. IIb C [88]
If a left atrial or ventricular thrombus is present, inspection and removal of the thrombus are recommended. I C
If an LAA thrombus is present, occlusion of the LAA should be considered. IIa C
Although RV and RA thrombi are less common, cardiac imaging to exclude them, in particular before
implantation of an RVAD, should be considered.
IIa C [71]
In case of implantation of a left ventricular assist device, removal of an RV thrombus may be considered. IIb C
In case of RVAD implantation in the RA, removal of an RV thrombus may be considered. IIb C
In case of RVAD implantation in the RA, removal of an RA thrombus is recommended. I C
In case of RVAD implantation in the RV, removal of an RV thrombus is recommended. I C
Miscellaneous conditions
A left thoracotomy approach may be considered in patients who have had prior cardiac surgery. IIb C [89]
LT-MCS implantation in patients who have active infective endocarditis is not recommended. III C [33]
Postponement of an LT-MCS implant may considered in patients who have had a recent myocardial infarction
affecting the left ventricular apex if the situation allows.
IIb C [90]
Surgical or interventional revascularization at the time of LT-MCS implantation may be considered in patients
with right ventricular ischaemia.
IIb C
ICD: implantable cardioverter defibrillator; LAA: left atrial appendage; LT-MCS: long-term mechanical circulatory support; RA: right atrium; RV: right ventricle;
RVAD: right ventricular assist device; VT: ventricular tachycardia.
Recommendations for concomitant cardiac condition including arrhythmias (Continued)
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specific definition has been validated, with the exception of the
Fried scale [94, 96]. Frailty leads to significantly longer duration of
mechanical ventilation, length of stay and long-term mortality in
patients with LT-MCS [47, 48, 95]. After LT-MCS implantation,
regression of frailty may occur [97]. Advanced age is a risk factor
for frailty and comorbidities. However, several retrospective studies
revealed acceptable outcomes after LT-MCS implantation in the
elderly. Therefore, age alone should not be used as an exclusion
criterion for LT-MCS implantation [98, 99].
Cardiac cachexia (CC) is the unintentional non-oedematous
weight loss of >5% over at least 6 months. CC is associated with
older age and can result in longer length of hospital stay and
higher costs. CC (19%) is among the most common comorbid-
ities of HF together with malignancies (34%) and chronic
obstructive pulmonary disease (29%). Pathophysiological mecha-
nisms of CC include metabolic and neurohormonal abnormal-
ities [100]. However, the preoperative health status Kansas City
Cardiomyopathy Questionnaire has limited association with out-
comes after ventricular assist device (VAD) implantation [101].
For assessment of nutritional status, the prognostic nutritional
index [serum (pre-) albumin and total lymphocyte count] might
be used as an indicator of a worse outcome [102].
Renal dysfunction (RD) in advanced HF should be evaluated and
categorized as primary or secondary dysfunction. LT-MCS implan-
tation may reverse secondary RD [37, 56, 71, 103]. Severe RD (glo-
merular filtration rate <30 ml/min) increases the risk of the
perioperative requirement for renal replacement therapy, early RV
failure, infections and hospital mortality in patients with an LVAD
[37, 56, 71, 103]. Primary RD should be ruled out. Primary non-
reversible renal disease with severe RD may contraindicate LT-MCS
implantation due to poor prognosis [37, 56, 71, 103]. Chronic hae-
modialysis should be considered as a relative contraindication for
LT-MCS placement in highly selected patients. There are limited
data on the safety of peritoneal dialysis while on LT-MCS support.
Preimplant major stroke is present in 3.6% of the patients
in the INTERMACS Registry; other cerebrovascular diseases are
present in 3.8%. Neurological and cognitive function should be
assessed before LT-MCS implantation [104]. No worldwide
accepted psychosocial assessment is available. The Stanford
Integrated Psychosocial Assessment for Transplant can, however,
certainly be used for LT-MCS candidates [105, 106].
Pre-LT-MCS evaluation of pulmonary function is manda-
tory [107]. There is a high prevalence of chronic obstructive
pulmonary disease among patients with HF that can lead to a
worse prognosis. Restrictive abnormalities and/or altered alveolo-
capillary transfer may be a consequence of chronic
pulmonary venous congestion. Re-evaluation after correction of
fluid overload is recommended. To assess pulmonary hypertension,
invasive haemodynamic assessment of pulmonary vascular resist-
ance (PVR) is mandatory. Normalization of high PVR following LT-
MCS support, thereby enabling a successful heart transplant (HTx),
has been shown previously [108, 109].
Polysomnography is recommended in case of suspected sleep
apnoea, drowsiness, periodic breathing and desaturation epi-
sodes, although the role of non-invasive ventilation in central
sleep apnoea syndrome has been questioned.
Non-thyroidal illness syndrome has low levels of plasma T3
and T4, increased levels of reverse-T3 and normal or slightly
decreased levels of thyroid-stimulating hormone. Non-thyroidal
illness syndrome is frequent in critically ill patients (prevalence of
18%) and has a negative prognostic role. The early postoperative
finding of low T3 syndrome is associated with a higher mortality
rate and complications [110, 111].
Diabetes is common in recipients of LT-MCS (43%) but, in
contrast to results from a previous study [28], does not increase
mortality or serious adverse event rates during LT-MCS support
[112, 113]. In a retrospective analysis (n = 244), LT-MCS therapy
was associated with improvement in diabetic control that was
attributed to improvements in cardiac output and normalization
of biochemical derangements [114]. More awareness of diabetic
patients with advanced HF is necessary [115].
Faecal occult blood testing during evaluation of potential can-
didate for LT-MCS is recommended. In the CF-VAD population,
gastrointestinal (GI) bleeding is common and is associated with
the occurrence of angiodysplasia [116] and acquired von
Willebrand syndrome [117].
Hepatic dysfunction may occur as hypoxic hepatitis [118] in
patients with acute HF or more commonly as ‘cardiohepatic syn-
drome’ in the setting of congestive HF [119–121]. Liver dysfunc-
tion is a predictor of poor outcome in patients with advanced
HF requiring LT-MCS [41]. However, the liver has outstanding
regeneration potential, which may occur after LT-MCS implanta-
tion [59, 63, 122–126]. Preoperative liver dysfunction influences
the levels of circulating coagulation proteins and affects postop-
erative blood product requirements [127].
Short- or long-term MCS may rescue patients with peripartum
cardiomyopathy [128]. Successful delivery in a patient with LT-
MCS has been described [129].
Recommendations for the management of non-cardiac comorbidities
Recommendation Class Level References
Malignancies
Evaluation for malignancies is recommended. I A
In patients with a proven malignancy and an expected survival of <1 year, implantation of long-term
mechanical circulatory support is not recommended.
III C
Pulmonary hypertension
Invasive haemodynamic assessment of pulmonary vascular resistance is recommended. I C [107]
In heart transplant candidates, normalization of elevated pulmonary vascular resistance in patients on long-term
mechanical circulatory support should be considered.
IIa B [108, 109,
130, 131]
Cardiac cachexia
Assessment of frailty and nutritional status using a frailty score and/or prognostic nutrition index prior to
implantation of long-term mechanical circulatory support may be considered.
IIb C [48, 96]
Continued
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8. SYSTEM SELECTION
8.1 Background
Implantable CF-LVADs represent the most common form
of LT-MCS device used. However, some situations require
temporary or permanent biventricular support and outcomes
of patients depend on the appropriate choice of MCS
strategy.
8.2 Evidence review
Centrifugal versus axial-flow implantable left ventricular
assist devices.
• The currently approved axial-flow and centrifugal LVADs
provide safe and effective circulatory support in a popula-
tion of patients with end-stage HF [138–150].
• Centrifugal LVADs may facilitate implantation and offer options
for different surgical approaches and strategies [151–154].
Renal dysfunction
Implantation of long-term mechanical circulatory support should be considered in case of reversible secondary
renal dysfunction.
IIa C [37, 56, 71,
103]
Implantation of long-term mechanical circulatory support may be considered in patients on chronic haemodialysis. IIb C [37, 56, 103]
Neurological function and disorders
Careful neurological examination is recommended for all candidates for implantation of long-term mechanical
circulatory support including assessment of dementia and mental status.
I C [104, 132]
Multidisciplinary evaluation of prognosis of survival and morbidity of patients with neuromuscular disorders is
recommended.
I C [133]
Adherence (medical therapy, alcohol, tobacco, psychological, psychiatric and social derangement)
Screening for psychological and psychiatric (including cognitive function) disorders and substance abuse is
recommended.
I C [104]
It is recommended that adherence (tobacco, alcohol and substance abuse), psychosocial risks and familial
support be evaluated.
I C [134]
In patients with frailty, psychiatric or neurological disorders, evaluation of their ability to operate the device is
recommended.
I C
Vascular disease
Screening for peripheral vascular disease is recommended. I C [67]
Coagulation and haematological disorders
Evaluation of all long-term mechanical circulatory support candidates for coagulopathies and hypercoagulable
states (e.g. thrombophilia) is recommended.
I C [135]
In patients with thrombocytopenia after exposure to heparin, testing for heparin-induced thrombocytopenia
should be considered.
IIa C [136]
Respiratory considerations
Spirometry as part of the patient work-up should be considered. IIa C [25, 37, 137]
Preoperative thoracic imaging should be considered as part of the overall risk/benefit evaluation. IIa C [25, 37, 137]
Diabetes
Screening for diabetes mellitus (including end-organ damage) before implant of long-term mechanical
circulatory support is recommended. For patients with poorly controlled diabetes, consultation with a
diabetologist is recommended.
I C
Implantation of long-term mechanical circulatory support in patients with diabetes with severe end-organ
complications is not recommended.
III C
Gastrointestinal disorders
Gastrointestinal bleeding in patients 50 years or older: faecal occult blood testing, gastroscopy and endoscopy
should be considered.
IIa C [116, 117]
Pregnancy
Contraception in women of childbearing age after implant of long-term mechanical circulatory support is
recommended.
I C
Long-term mechanical circulatory support in the setting of pregnancy is a multidisciplinary challenge and may be
considered.
IIb C [128, 129]
Recommendations for the management of non-cardiac comorbidities (Continued)
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Left ventricular assist device versus biventricular assist
device: impact of right heart function.
• A combination of clinical, haemodynamic, echocardio-
graphic and biochemical parameters might be useful
to assess right heart function preoperatively and to predict
the need for perioperative mechanical RV support
(Supplementary Material, Table S3).
• Levosimendan prior to LVAD implantation might be used to
reduce the risk of right ventricular failure, although evidence
is limited [155, 156].
• Echocardiographic assessment of RV geometry, contractility
and valvular function (Supplementary Material, Table S4)
prior to VAD implantation can be useful to evaluate the
need for RV support [157–161].
• Patients with adequate right heart function who only require
LVAD support have better survival rates, lower adverse event
rates and superior quality of life than patients requiring
BiVAD or TAH support [147, 162–173].
• RV failure requiring RVAD support is the most important
risk factor for early death in LVAD recipients [170, 174–178].
• Temporary RVAD support should be considered in all recipi-
ents of an implantable LVAD, even in case of low RV failure
risk score (RVAD required in 6–28% of LVAD recipients)
[147, 178].
• Delayed institution or rescue implantation of RV support
further increases the risk of morbidity and mortality com-
pared to early RVAD implantation [147, 168, 169, 171, 179].
8.3 Biventricular assist device
Several BiVAD configurations exist: paracorporeal pulsatile-flow
BiVAD, an implantable LVAD coupled with a concurrent paraco-
poreal or percutaneous RVAD or two implantable CF-LVADs.
These conficurations provide comparable outcomes [173]. The
insertion of two implantable CF-LVADs as BiVAD configuration is
predominatly performed at experienced centers. However, the
application of a CF-LVAD as an implantable RVAD remains an
off-label use.
8.4 Temporary right ventricular assist device
• A temporary RVAD can be used while awaiting recovery of
the RV after LVAD implantation and can be substituted with
long-term RVAD support if required [170, 180].
• A temporary RVAD can be implanted percutaneously [181,
182] or surgically through a less invasive or sternotomy
approach [183–186].
8.5 Longer-term right ventricular assist device
• Implantable BiVAD (e.g. 2 CF-LVADs) support might be con-
sidered in patients at high risk of RV failure having bridge to
transplant [81, 187–191].
• Off-label use of implantable axial-flow or centrifugal LVADs
has been adopted as RVAD support in conjunction with
implantable LVAD support as an alternative to extracorpor-
eal BiVAD or TAH implantation [192–196].
8.6 Total artificial heart
• TAH implantation is an option in bridge-to-transplant
patients with biventricular failure and provides results com-
parable to those of BiVAD support [187, 193, 197–202].
• TAH implantation may be considered in patients with ana-
tomical or other conditions that are not well served with 2
implantable LVADs or extracorporeal BiVAD such as in
patients with small/non-dilated ventricles or patients requir-
ing significant concomitant repair, e.g. restrictive/hypertro-
phic cardiomyopathy, cardiac tumour [203–206], complex
postinfarction ventricular septal defect [207, 208] and con-
genital heart disease (CHD) with end-stage HF [209, 210].
• TAH might have a lower stroke incidence compared to
BiVAD, resulting in a trend towards better survival [193,
211].
Recommendations for LT-MCS system selection
Recommendation Class Level References
For predicting right heart failure,
the use of clinical, haemody-
namic, echocardiographic and
biochemical parameters should
be considered.
IIa C
[170–174]
In patients with severe chronic
biventricular failure, a BiVAD or a
TAH should be considered. IIa B
[81, 147,
162–178,
187–191,
200,
203–208,
212]
In patients with refractory right
heart failure after implantation of
an LVAD, early implantation of a
temporary RVAD should be
considered.
IIa C
[147, 168,
169, 171,
179]
Early RVAD implantation in case
of right heart failure to decrease
morbidity and mortality should
be considered.
IIa C
[147, 168,
169, 171,
179, 186]
Implantable BiVAD support may
be considered in patients at high
risk of right ventricular failure.
IIb C
[81,
187–191]
Two CF-LVADs as an implantable
BiVAD may be considered.
IIb B [192–196,
212, 213]
A TAH may be indicated in
patients with biventricular failure,
restrictive cardiomyopathy, car-
diac tumours or large ventricular
septal defects.
IIb C
[187, 193,
197–201]
In patients with anatomical or
other clinical conditions that are
not well served with an LVAD or
BiVAD, implantation of a TAH
may be considered.
IIb C
[203–208]
BiVAD: biventricular assist device; CF: continuous-flow; LT-MCS: long-term
mechanical circulatory support; LVAD: left ventricular assist device; RVAD:
right ventricular assist device; TAH: total artificial heart.
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9. ANAESTHETIC MANAGEMENT
The clinical status of patients requiring LT-MCS varies consider-
ably, from well-compensated (with poor cardiac reserve) to
cardiogenic shock. Therefore, perioperative anaesthetic manage-
ment is challenging [214–216].
9.1 Monitoring
For central venous access, ultrasound guidance is preferred due to
the high incidence of thrombosis caused by previous indwelling
catheters or transvenous pacemaker leads [217–220]. Although
the impact of a pulmonary artery catheter on outcome has not
been demonstrated for cardiac surgery [221], in relation to MCS
implantation, pulmonary artery catheters provide valuable infor-
mation including mixed venous oxygen saturation, pulmonary
arterial pressure and vascular resistance that can guide intraopera-
tive therapy decisions [222–224]. Neuromonitoring with electro-
encephalography is aimed at avoiding anaesthesia awareness
[225]; cerebral perfusion can be assessed by estimating tissue oxy-
gen saturation using near infrared spectroscopy [226].
9.2 Anaesthetic drugs
For induction, the use of propofol is not recommended due to
its depressing effect on myocardial contractility and systemic
vascular resistance. Therefore, etomidate (0.2–0.3 mg/kg) or a
combination of midazolam and sufentanil are the preferred
induction agents because myocardial contractility and systemic
vascular resistance are unaffected [227]. Analgesia could be pro-
vided by short-acting opioids such as fentanyl or sufentanil.
Anaesthesia is maintained using continuous infusion of propofol
and an opioid.
Mechanical ventilation should avoid hypoxia and hypercarbia,
which could result in an increase of PVR [228]. Protective
ventilation settings with tidal volumes of 6–8 ml/kg and appro-
priate positive end expiratory pressure reduce the risk of
ventilator-associated lung injury [229].
Transoesophageal echocardiography (TOE) has become an
essential diagnostic and monitoring tool during LT-MCS implan-
tation [230, 231]. Preprocedural TOE may identify intracavitary
thrombus: thrombus size, localization and mobility may affect
the surgical strategy. Furthermore, patent foramen ovale, other
atrial and ventricular septal defects can be identified. If evalua-
tion is inconclusive, contrast can be added.
Aortic regurgitation (AR) decreases the efficiency of LT-MCS.
Therefore, it is recommended to not only assess AR before sur-
gery but also when the patient is on cardiopulmonary bypass
(CPB). CPB mimics the haemodynamic situation of VAD support
with similar pressure and flow in the ascending aorta. In this set-
ting, a final decision on aortic valve surgery can be made for
borderline cases. Furthermore, TOE provides valuable informa-
tion about right ventricular function and the tricuspid valve and
can affect (concomitant) surgery [232].
Intraprocedural imaging of the inflow and outflow cannulas of
the device is mandatory [233, 234]. Furthermore, TOE can help
determine pharmacological support and pump speed settings while
the patient is weaned from CPB, with special attention to the intra-
ventricular septum in the 4-chamber view. Bulging of the intraven-
tricular septum to the left and excessive unloading of the left
ventricle (LV) indicate either excessive LVAD speed or RV failure.
Patients at risk of RV failure may benefit from primary phar-
macological support to increase myocardial contractility and to
decrease PVR using a combination of epinephrine, milrinone
and inhaled pulmonary vasodilators [e.g. inhaled nitric oxide
(iNO) or/and iloprost]. Observational studies have demonstrated
a beneficial effect of iNO therapy [235, 236]. However, iNO did
not significantly reduce the incidence of RV failure in a multi-
centre randomized study [237]. Expert panels concluded that it is
reasonable to consider using iNO during LVAD implantation
[238, 239].
Recommendations for anaesthetic management during LT-MCS implantation
Recommendations Class Level References
Monitoring
The introduction of an arterial line in advance of anaesthesia induction is recommended. I C [214–216]
Use of a central venous line is recommended. I C [214–216]
A pulmonary artery catheter should be considered. IIa C [222–224]
Neuromonitoring with electroencephalography may be considered. IIb C [225]
Neuromonitoring with near infrared spectroscopy should be considered, especially in off-pump implantation. IIa C [243]
Periprocedural transoesophageal echocardiography
It is recommended that the following assessments be performed using periprocedural transoesophageal echo-
cardiography: intracavitary thrombus identification, detection of patent foramen ovale and other
intracardiac shunts, assessment of aortic regurgitation, right ventricle assessment, inflow cannula positioning
and outflow cannula positioning.
I C
[230]
Assessment of right ventricular failure
Transoesophageal echocardiography guidance for weaning from CPB/extracorporeal life support is
recommended.
IIa C
iNO, milrinone and phosphodiesterase type 5 inhibitors to lower pulmonary vascular resistance should be
considered.
IIa B [236,
244–246]
CPB: cardiopulmonary bypass; iNO; inhaled nitric oxide; LT-MCS: long-term mechanical circulatory support.
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Early criteria for postprocedural diagnosis of RV failure are car-
diac output <2.0 l/min/m2, mixed venous oxygen saturation
<55% and mean arterial pressure <50 mmHg [237]. High ino-
tropic requirements and RV dilatation with concomitant collapse
of the LV are signs of RV failure and should prompt the addition
of temporary MCS for the RV [186].
If CPB is used, the suggested heparin dose is 400 IU/kg with a
target activated clotting time of >400 s. If the patient is on extrac-
orporeal membrane oxygenation (ECMO) or the ECMO remains
implanted for a period after LVAD implantation (e.g. for support
of the RV), a dose of 100 IU/kg heparin and a target activated
clotting time of 160–180 s is recommended. Similarly, off-pump
LVAD implantation is usually performed under heparin 100 IU/
kg. Thromboelastometry- and thromboelastography-guided
therapy results in a significantly lower re-exploration rate [240,
241] and a decrease in the incidence of postoperative acute kid-
ney injury [242].
After LT-MCS implantation, preload should be optimized
to ensure adequate VAD flows. However, overloading of the
RV must be avoided. Any volume therapy should also take
into account the likely quantity of blood products required
to restore the coagulation status. To titrate volume status,
assessment with TOE and the central venous pressure are
essential.
10. OPERATIVE TECHNIQUE
The operative technique is subject to device-specific features as
well as to the individual surgeon and institutional preferences.
These recommendations summarize common steps in the surgi-
cal approach. However, patient-specific conditions, clinical status
and the need for concomitant procedures may necessitate alter-
native or additional steps.
Recommendations for operative technique
Recommendations Class Level References
Use of circulatory assistance during implantation: implant strategy
The use of cardiopulmonary bypass during implantation of a long-term mechanical circulatory support device
should be considered. IIa C
[37, 138,
141, 145,
247]
In case of no necessary concomitant intracardiac procedure, implantation of LT-MCS on extracorporeal life
support or off-pump implantation may be considered.
IIb C [248]
In off-pump mechanical circulatory support implantation, secured vascular access for bail-out cardiopulmonary
bypass is recommended.
I C [249, 250]
Mechanical circulatory support site preparation
For non-intrapericardial devices, creation of the pump pocket by left hemidiaphragm transection to
accommodate the pump is recommended.
I C [37]
For intrapericardial devices, in case of pericardial pouch-device mismatch, incising the pericardium to allow
pump placement in the left pleural cavity may be considered.
IIb C [247]
Implantable left vascular assist device—inflow cannula placement
Inflow cannula placement into the left ventricle is recommended. I A [37, 138]
The use of transoesophageal echocardiography to check the inflow cannula position is recommended. I C [37]
Placement of the inflow cannula parallel to the septum is recommended. I B [37]
Inflow cannula placement in the inferior left ventricular wall may be considered. IIb C
Inflow cannula placement in the lateral left ventricular free wall is not recommended. III C [37]
Apical cuff positioning
Apical cuff affixing with the sew first and then core technique, without other intraventricular manipulation
necessary, is recommended.
I C [37, 251]
Apical cuff affixing with the sew first and then core technique with interrupted pledgeted sutures or continuous
suture should be considered.
IIa C [251, 252]
Apical cuff affixing with the core first and then sew technique is recommended if intraventricular procedures, e.g.
thrombus removal, mitral valve repair, are necessary.
I C [37, 251]
Continued
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In the setting of acute left ventricular myocardial infarction due to friable tissue, the sew first and then core
technique with use of circular reinforcement strips and surgical glue may be considered.
IIb C [251]
Apical cuff affixing with the core first and then sew technique with interrupted pledgeted reverse sutures may
be considered.
IIb C [251]
In the setting of hypertrophic or non-compaction cardiomyopathies, a partial intracavitary excision prior to the
apical cuff affixing may be considered.
IIb C [253, 254]
In the setting of acute left ventricular myocardial infarction with friable tissue of the apex, the use of temporary
mechanical circulatory support may be considered to defer a long-term mechanical circulatory support
implant.
IIb C
Implantable left ventricular assist device: outflow graft
Performing the outflow graft anastomosis on the ascending aorta is recommended. I C [37, 247]
Performing the outflow graft-ascending aortic anastomosis at a 45 angle should be considered to reduce the
risk of late aortic insufficiency.
IIa C [37, 247]
The use of surgical glue to secure the haemostasis of the graft-aorta anastomosis may be considered. IIb C [37]
Using the longitudinal line marker on the outflow graft to avoid twisting is recommended. I C [37]
Positioning the outflow graft along the inferior right ventricular surface and between the right atrium and
pericardium to avoid crossing the right ventricular outflow tract should be considered.
IIa C
Positioning the outflow graft through the transverse sinus onto the posterolateral aspect of the ascending aorta
may be considered.
IIb C [255]
Implantable left ventricular assist device: alternative implant strategy/left thoracotomy approach
An intrapericardial course of the outflow graft in patients without previous cardiac surgical procedures is
recommended.
I C [37, 247]
The outflow graft anastomosis to the descending aorta may be considered in redo patients and patients with a
severely calcified ascending aorta.
IIb C [152–154,
256, 257]
A left pleural cavity course of the outflow graft in redo implants with the anastomosis on the ascending aorta
may be considered.
IIb C
In redo implants or for patients in whom an aortic anastomosis is not amenable, anastomosis of the outflow
graft to the axillary artery may be considered. In this scenario, distal banding of the axillary artery to avoid
hyperperfusion may be considered.
IIb C
[153, 258]
Driveline externalization
The course of the driveline with an intermediate incision (C-shape) to maximize the pump-to-exit site distance
and to alleviate traction forces may be considered.
IIb C [259]
A partial course of the driveline through the rectus abdominis muscle to enhance the barrier for infection is
recommended.
I C [260]
It is recommended that the portion of the driveline covered in velour is completely intracorporeal. I C [259, 260]
Air embolism prevention
Carbon dioxide insufflation within the surgical field is recommended. I B [261, 262]
Having the patient in the Trendelenburg position at the time of de-airing may be considered. IIb C [37]
Liberal de-airing via the outflow graft is recommended with on-pump surgery. I C [37]
Oversewing or glue application on the outflow graft de-airing spot to obviate late bleeding in patients having
anticoagulation therapy may be considered.
IIb C
Careful de-airing strategy in off-pump implantation should be considered. IIa C [263]
Active suction (needle venting) may be considered. IIb C
Alternative implant surgical strategy
Left anterior thoracotomy at a level of the apex validated by echocardiography or computed tomography is
recommended.
I C [151–154]
A partial upper sternotomy for the outflow graft anastomosis may be considered. IIb C [151, 152,
154]
Continued
Recommendations for operative technique (Continued)
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11. PAEDIATRIC OPERATIVE TECHNIQUES
11.1 Introduction
The success rate of bridging children with MCS to a transplant or
recovery using pulsatile or CF devices has improved with time. In
the latest PEDIMACS report, an 84% 6-month survival rate on
devices was reported with a transplant rate of nearly 50% [275],
whereas the first Paedi-EUROMACS report shows a 6-month sur-
vival of 81% and a transplant rate of more than 50% [276].
Paediatric data on intracorporeal devices from EUROMACS dem-
onstrated an on-device survival rate of 89% at 12 months [277].
Originally, the MCS devices used were mainly paracorporeal
devices. More recently, an increase in the use of CF-LVAD in
paediatric patients and patients with CHD has been reported
[275, 278–281]. The obvious advantage is the ability to discharge
these young patients home [282–286].
11.2 Small children—system selection
Device selection in children and patients suffering from CHD (see
section below) differs significantly from that in adults with ana-
tomically normal hearts and also differs substantially among
paediatric groups depending on age and the type of CHD of the
patient [275, 287, 288]. The Berlin Heart EXCORV
R
Paediatric VAD
is currently the only VAD specifically designed and approved for
the paediatric population in the USA, Europe and Canada.
In paediatric patients with a body surface area >1.2 m2 requiring
MCS, the use of an implantable CF-LVAD is feasible because
A right lateral thoracotomy for the outflow graft anastomosis may be considered. IIb C [151, 153]
An alternative implant strategy with the outflow graft tunnelled via pleural cavities in redo implants without the
need for major concomitant procedures may be considered.
IIb C
In patients with a history of cardiac surgery through a median sternotomy and who do not require concomitant
cardiac surgery other than implantation of long-term mechanical circulatory support, implantation through a left
lateral thoracotomy with connection of the outflow graft to the descending aorta may be considered.
IIb C
Closing surgical operation field considerations
Liberal use of chest and pleural drains is recommended. I C [37]
In the case of major coagulopathy, a provisional chest closure with surgical packing may be considered. IIb C [264]
In patients with the prospect of a heart transplant, strategies to limit adhesions during implantation should be
considered.
IIa C
Biventricular support
Use of temporary short-term right heart support to allow for a subsequent explant without sternal reopening
should be considered. Various possibilities can be considered: cannulation of the right atrium via the femoral
vein for blood inflow and for blood return cannulation of vascular graft attached to the pulmonary artery or
cannulation through the jugular vein. An additional option may be an endovascular microaxial pump inserted
into pulmonary artery.
IIa C
[265]
For implantable right ventricular assist device support, insertion of the inflow cannula insertion into the right
atrium should be considered.
IIa C [265, 266]
For implantable right ventricular assist device support, insertion of the inflow cannula into the right ventricle
may be considered.
IIb C [266, 267]
Long-term paracorporeal support
Apical cannulation of the left ventricle should be considered for the left side of the pump. IIa C [188]
In patients with restrictive/obstructive cardiomyopathy, cannulation in the left atrium may be considered. IIb C [268]
Total artificial heart
An atrial connection at the level of the atrioventricular valves and outflow grafts connected to the great vessels
are recommended. I C
[192, 193,
196, 206,
269, 270]
Long-term mechanical circulatory support explant
Complete circulatory support system explant is recommended in cases of active device infection or in patients
at a high risk of infective complications.
I C [271]
After mechanical circulatory support explant for infection, stabilization with temporary mechanical circulatory sup-
port in conjunction with comprehensive antimicrobial therapy may be considered as a bridge to reimplantation.
IIb C [263]
After myocardial recovery without signs of infection, removal of the pump with a dedicated titanium sintered
plug, outflow graft ligation and removal of the driveline should be considered where possible.
IIa C [267, 272]
After heart recovery without signs of infection, decommissioning with outflow graft ligation or endovascular
occlusion with partial removal/internalization of the driveline may be considered.
IIa C [273, 274]
LT-MCS: long-term mechanical circulatory support.
Recommendations for operative technique (Continued)
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results are non-inferior to those with extracorporeal devices [275,
289, 290], and discharge from the hospital is possible, resulting in
a better quality of life [275, 277, 284, 285, 290]. In adults, CF-VADs
have improved survival and greater freedom from stroke and
device failure compared with pulsatile devices [147]. This result
seems to be true also for paediatric patients with a body surface
area >1.2 m2 and without CHD [275, 277, 279, 290].
11.3 Single ventricle—Fontan haemodynamics
Approximately 5–10% of children born with CHD suffer from an
underdeveloped LV or RV, leading to single ventricle physiology.
Large studies on the use of MCS in patients with a single ventricle
are lacking. Only case reports or small case series have been pub-
lished, and they report high mortality rates [283, 291, 292]. However,
implantation of VADs in various locations seems to be feasible.
The feasibility of VAD support for Glenn circulation has been
reported with mixed results [283, 292, 293]. After the Fontan circula-
tion has been created, there are 2 possibilities of failure: systemic
ventricular failure or failure at the level of the cavopulmonary con-
nection. Currently available VADs are designed to support the failing
ventricle. Nevertheless, available devices have been used for cavo-
pulmonary support in patients with failing Fontan circulation [294,
295]. Others use clinically available VADs as a bridge to transplant
[296–299]. For patients with failing Fontan circulation, TAH might
be a viable option [300]. In cases of failing Fontan circulation and
ventricular failure, the BiVAD remains an option but requires revi-
sion of the Fontan pathway to allow the separation of the systemic
venous and pulmonary circulations, which can be very demanding.
11.4 Total artificial heart
A certain percentage of patients require biventricular support with
either BiVAD placement or implantation of a TAH. The 70-cc TAH
(SynCardia Systems Inc., Tucson, AZ, USA) is currently the only
Food and Drug Administration (FDA)-approved and Conformite´
Europe´enne (CE)-marked TAH licensed for bridge to transplant or
destination therapy. However, this device is limited to patients
with a larger chest cavity with adequate intrathoracic space to
accommodate this device. The 50 cc-TAH (currently under investi-
gation for FDA approval) is more appropriate for use in smaller
patients, especially in complex cases who have had limited clinical
options such as failing Fontan circulation [300]. Unsurprisingly,
reported outcomes in patients <_21 years supported with a TAH
seem to be inferior to LVAD-only implantation [301].
11.5 Special cases
Besides the ‘single ventricle physiologies’, CHD includes a wide
spectrum of cardiac anatomical configurations, including surgi-
cally corrected transposition of the great arteries using the atrial
switch procedure (Senning or Mustard operation) at infancy/
childhood or patients with corrected congenital transposition of
the great arteries. VAD placement in these patients is possible,
and some patients will benefit from VAD support [275, 302–307].
However, limited data make standardized recommendations
impossible. Each case has to be discussed individually, preferably
by a dedicated heart team. Adult CHD and non-adult CHD
patients supported by LVADs demonstrate similar survival
regardless of cardiac anatomy [275].
12. POSTOPERATIVE MANAGEMENT IN THE
INTENSIVE CARE UNIT
Successful outcomes after cardiac surgery for LT-MCS depend on
optimum postoperative care in the intensive care unit. Key ele-
ments of this multifaceted bundle of care include appropriate
monitoring, with specific attention to right ventricular function,
optimized volume and inotropic support, adequate management
of sedation, analgesia, and ventilation and appropriate anticoa-
gulation and transfusion strategies. Patients supported with LT-
MCS should have standard monitoring used in the institution for
patients after cardiac surgery. Additional monitoring specific for
these patients is presented below.
Recommendations for paediatric operative techniques
Recommendation Class Level References
Device selection in small children
Implantation of a device with
patient-device size mismatch is
not recommended.
III C
If mid- to long-term mechanical
circulatory support is anticipated,
durable implantable or extracor-
poreal devices should be consid-
ered over extracorporeal life
support.
IIa B
[308–310]
In children in need of mechanical
circulatory support, implantation
of an intracorporeal continuous-
flow left ventricular assist device
and subsequent discharge home
should be considered.
IIa C
[275, 277,
278, 284,
285, 289,
290, 311]
Use of a SynCardia total artificial heart
In complex congenital heart dis-
ease, patients, especially those
with biventricular failure, with an
adequate chest cavity and/or
adequate intrathoracic space, a
TAH may be considered as a
bridge to transplant or as desti-
nation therapy.
IIb C
[301]
If a TAH placement is planned, a
virtual fit/implantation is
recommended.
I C
[312–314]
Patients with congenital heart disease requiring mechanical
circulatory support
It is recommended to have
recently obtained documenta-
tion of cardiac morphological
and ventricular physiological
data after the last surgery, includ-
ing the presence of shunts, col-
lateral vessels and the location
and course of great vessels in
patients with congenital heart
disease undergoing evaluation
for mechanical circulatory sup-
port implantation.
I C
[71, 275,
315, 316]
TAH: total artificial heart.
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13. ANTICOAGULATION
13.1 Background
LT-MCS devices require antithrombotic therapy due to the pres-
ence of the artificial surfaces of the pump and the modified fluid
dynamic pattern of the blood accompanied by shear forces.
Anticoagulation for LT-MCS comprises 3 different periods: pre-
operative, intraoperative and early postoperative. Management
is often similar to that of other cardiac surgery procedures [64];
however, some situations require specific considerations as out-
lined below. Each phase has distinct issues and requires specific
management. Long-term antithrombotic therapy is more
standardized, although patients may tread a fine line between
bleeding and thrombosis. Furthermore, the optimal long-term
regimen of anticoagulation should be tailored to the recipient
and the device type. In this context, the development of clinical
analysis tools and/or risk scores is encouraged.
13.2 Description of evidence
Preoperative conditions. Normalization of coagulation
before LT-MCS implantation is crucial to avoid the postoperative
cascade of bleeding, transfusions and volume overload, RV fail-
ure and surgical re-exploration. Preoperative temporary MCS, in
Recommendations for postoperative management in the intensive care unit
Recommendation Class Level References
Monitoring
In postoperative patients with mechanical circulatory support, continuous electrocardiography, pulse oximetry,
central venous pressure and invasive arterial blood pressure monitoring are recommended.
I C
Miniaturized transoesophageal echocardiographic probes that can be maintained in the oesophagus in situ for
up to 72 h may be considered to assist in the management of fluid resuscitation and to diagnose complications.
IIb C [317]
A pulmonary artery catheter should be considered to assist in the management of fluid resuscitation and to
diagnose complications in patients receiving an LVAD and at risk of postoperative RV failure.
IIa C [71, 318]
Transpulmonary thermodilution and pulse contour-derived measurement of cardiac output are inadequate in
continuous-flow ventricular assist device and biventricular assist device settings and are therefore not
recommended.
III C
Postoperative laboratory monitoring, including daily measurement of plasma free haemoglobin and lactate
dehydrogenase, is recommended.
I C
Right ventricular failure in patients with a left ventricular assist device
Regular echocardiographic scans should be considered to monitor RV function in patients supported by an
LVAD.
IIa C [317, 319,
320]
Echocardiography is recommended to guide weaning from temporary RV support. I B [321, 322]
Inhaled NO, epoprostenol (or prostacyclin) and phosphodiesterase 5 inhibitors may be considered to reduce
right heart failure after LVAD implantation.
IIb C [323–327]
Inotrope and vasopressor support
Norepinephrine should be considered as a first-line vasopressor in case of postoperative hypotension or shock. IIa B [9, 328, 329]
Dopamine may be considered in case of postoperative hypotension or shock. IIb B [9, 328, 329]
The combination of norepinephrine and dobutamine should be considered instead of epinephrine in case of
postoperative hypotension and low cardiac output syndrome with RV failure.
IIa C [9, 71, 330,
331]
Epinephrine may be considered in case of postoperative hypotension and low cardiac output syndrome with
RV failure.
IIb C
Phosphodiesterase 3 inhibitors may be considered in patients with long-term mechanical circulatory support
with postoperative low cardiac output syndrome and RV failure.
IIb C [332, 333]
The use of levosimendan in case of postoperative low cardiac output syndrome may be considered. IIb A [334, 335]
Postoperative mechanical ventilation
Avoidance of hypercarbia that increases pulmonary artery pressure and RV afterload is recommended. I C
Bleeding and transfusion management
If mediastinal drainage exceeds 150–200 ml/h in the early postoperative phase, surgical re-exploration should
be considered.
IIa C
Activated recombinant factor VII may be considered as a salvage therapy for intractable haemorrhage after
correction of bleeding risk factors and after exclusion of a surgically treatable cause of bleeding.
IIb C [336, 337]
LVAD: left ventricular assist device; NO: nitric oxide RV: right ventricular.
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particular, requires an antithrombotic regimen with intravenous
drugs. Coagulopathy is inevitably present due to activation and
consumption of coagulation factors secondary to cardiogenic
shock and exposure to biomaterials and devices. This condition
requires specific and more aggressive preoperative treatment.
Intraoperative conditions. Intraoperative full anticoagula-
tion is recommended and, in line with other cardiac surgery pro-
tocols, with full reversal and restoration of blood components
and coagulation factors at the end [64], except for off-pump sur-
gical techniques or implant of extracorporeal life support, where
a lower dose of heparin may be considered.
Postoperative conditions. Postoperative early anticoagula-
tion is mandatory to prevent thrombotic events. Intravenous
administration is the primary choice: unfractionated heparin is
commonly used, but successful use of direct thrombin inhibitors
has been reported. Anticoagulation can be commenced 8 h after
surgery with all devices if bleeding is <50 ml/h [338]. Initially, the
target activated partial thromboplastin time is 40 s; it is progres-
sively increased to 55–60 s within the first 48–72 h postopera-
tively. Oral anticoagulation with the vitamin K antagonist should
be initiated once the clinical condition is considered stable and
oral intake is possible. The international normalized ratio (INR)
target is set according to device recommendations for modern
LT-MCS devices. The INR target is between 2.0 and 3.0.
Acetylsalicylic acid is routinely administered according to device
specifications. The use of new oral anticoagulants is currently not
recommended.
Measurement of both the activated partial thromboplastin
time and factor Xa are recommended for monitoring anticoagu-
lation therapy. Bridging with intravenous heparin is recom-
mended if the INR is <2.0 and in cases of planned invasive
procedures or non-cardiac surgical procedures for perioperative
bridging. Low-molecular-weight heparin may be considered as
well.
Frequent INR checks using home INR monitoring and dedi-
cated staff (for instance, trained pharmacists) permit strict antico-
agulation management [339, 340]. Intravenous direct thrombin
inhibitors such as bivalirudin and argatroban should be used as
alternative anticoagulation agents for patients with heparin-
induced thrombocytopenia.
Antithrombotic therapy should be patient-tailored during the
time on support and in the different clinical situations. Technical
equipment necessary for in-depth analysis is not yet available for
point-of-care testing [341], thus preventing a more detailed
approach in routine clinical practice.
Recommendations for the use of anticoagulation during LT-MCS
Recommendations Class Level References
Management of anticoagulation preoperative, perioperative and postoperative of LT-MCS implantation
If intraoperative extracorporeal life support or off-pump implantation is performed, administration of a reduced
dose of heparin may be considered.
IIb C
Early postoperative anticoagulation starting with intravenous anticoagulation, followed by vitamin K
antagonists, is recommended.
I C
The use of low-molecular-weight heparin as an early postoperative anticoagulation regimen should be
considered.
IIa C [341]
A postoperative international normalized ratio target between 2.0 and 3.0 is recommended. I C
The use of acetylsalicylic acid is recommended. I C
The use of low-molecular-weight heparin for bridging during long-term support is recommended. I C
Re-evaluation of antithrombotic therapy during bleeding episodes is recommended. I C
The use of novel oral anticoagulants is not recommended. III B [342]
Management of anticoagulation in the event of bleeding episodes
For a major bleeding event, discontinuation of anticoagulation and reversal with blood components and
coagulation factors are recommended.
I C [343]
For minor bleeding, if the INR is above the therapeutic range, adjustment of anticoagulation agents should be
considered.
IIa C
In all cases of bleeding, exploration and treatment of a bleeding site should be considered. IIa C [344]
After resolution of the first bleeding episode, discontinuation of long-term acetylsalicylic acid should be
considered.
IIa C
INR: international normalized ratio; LT-MCS: long-term mechanical circulatory support.
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14. REHABILITATION
14.1 Background
LT-MCS devices are implanted in patients with end-stage HF
who commonly present with severely impaired functional
capacity. Despite the lack of generally accepted recommenda-
tions for patients with LT-MCS, evidence is gathering that cardiac
rehabilitation is beneficial. The goal is to return an MCS-
supported patient to a normal and independent life. Besides the
typical goals of cardiac rehabilitation, which include improve-
ments in functional capacity and motor strength, specific addi-
tional goals in patients with LT-MCS are to educate them to
understand the operation and handling of the device, self-
management of sub-therapeutic INR, driveline exit site care as
well as psychological and social counselling. In addition to the
index rehabilitation immediately after LT-MCS implantation,
repeated rehabilitation can become necessary in patients who
exhibit adverse events (e.g. neurological complications) or those
presenting with extreme deconditioning.
14.2 Evidence review
All patients after LT-MCS implantation should undergo cardiac
rehabilitation in a rehabilitation centre familiar with the special
challenges of MCS [71, 345]. To achieve independence and
mobility in daily life, a multimodal rehabilitation programme
consisting of endurance and strength training should be com-
bined with education on handling the device and peripherals as
well as anticoagulation self-management. Patients with neurolog-
ical complications after VAD implantation should undergo reha-
bilitation in a centre with combined cardiac and neurological
rehabilitation facilities.
Exercise and strength training should be performed in accord-
ance with the recommendations for patients with HF and has
repeatedly been shown to be safe in patients with LT-MCS
[346–348]. During the index rehabilitation, exercise training
should be performed using bicycle ergometry to minimise the
risk of falls or other accidents. Exercise training can be guided by
the perceived level of exertion as measured by the modified
Borg Scale and should be performed at a higher level (around
13), which accounts for training between the anaerobic thresh-
old and the respiratory compensation point [348–350].
Alternatively, a baseline cardiopulmonary stress test can be used
to guide exercise training. This approach has been shown to sig-
nificantly improve peak VO2 in several series of patients with LT-
MCS from baseline values as low as 10 to >14 ml/kg/min at dis-
charge [348, 350, 351]. Strength training should focus on the
muscle groups of the lower extremities, which are important for
mastering the activities of daily life (standing up, walking per-
formance) and are also prone to early deconditioning in critical
illness [352]. Specifically, leg press, leg extensor, leg flexor, lower
limb abductors and adductors should be trained [352]. Similar to
exercise training, the appropriate level of exertion can be deter-
mined using the modified Borg Scale [348, 351, 353]. Structured
walks and other group activities can complement exercise and
strength training. These should further be complemented by
physiotherapy and occupational therapy that are tailored to the
individual patient’s needs.
Patients should be educated about the importance of fluid
balance and treatment compliance. In addition, patients should
be educated about home INR monitoring and INR self-
management to promote independence after discharge (see
Chapter 13).
Patients and caregivers should be educated about handling
the assist device as well as the required actions to typical alarms.
15. OUTPATIENT CARE
15.1 Mechanical circulatory support programme
organization
An LT-MCS programme requires organization, planning and
appropriate personnel to constitute a core MCS team [25, 37, 71,
137, 284, 354–362]. Mid- and long-term success for outpatients
on LT-MCS therapy depends on a multidisciplinary approach.
Such success is achieved by combining the expertise of MCS
coordinators, advanced HF cardiologists, cardiovascular surgeons
and other health care providers.
15.2 Discharge after ventricular assist device
implantation
Successful discharge planning begins preoperatively, with assess-
ment of the cognitive abilities of the patients, their support
Recommendations for rehabilitation after LT-MCS implantation
Recommendations Class Level References
Cardiac rehabilitation is recom-
mended for patients with long-
term mechanical circulatory
support.
I B
[345, 347,
348]
Rehabilitation in a centre familiar
with patients with long-term
mechanical circulatory support is
recommended.
I C
[345]
Psychosocial rehabilitation
should be considered.
IIa C
Rehabilitation including a combi-
nation of exercise and strength
training is recommended.
I C
[352]
Exercise training using a level of
perceived exertion or cardiopul-
monary stress testing should be
considered.
IIa C
[350]
Physiotherapy and occupational
therapy, depending on the indi-
vidual’s needs, should be
considered.
IIa C
Educating patients on interna-
tional normalized ratio self-mon-
itoring should be considered.
IIa C
It is recommended that patients
and caregivers are educated
about handling long-term
mechanical circulatory support
peripherals and required reac-
tions to typical alarms.
I C
LT-MCS: long-term mechanical circulatory support.
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system and home environment [25, 37, 71, 137, 284, 354–360].
Training of patients, family and other designated caregivers
should be performed in the implanting hospital by the LT-MCS
team.
A clear algorithm for when and how to seek help, including a
synoptic card placed in the pocket and in the room of the
patient at home with emergency instructions and contacts, is
mandatory [25, 37, 71, 137, 284, 354–360]. The MCS team is
responsible for informing the general practitioner, the referring
physician and the emergency support personnel of the dis-
charge of the patient with MCS. Those involved with the patient
should be provided with basic knowledge of the concepts of
MCS.
It is recommended that discharged patients regularly visit the
outpatient clinic. During each visit, the following procedures
should be considered: physical examination with special atten-
tion for the driveline exit site and blood pressure (BP), laboratory
testing (including coagulation and markers of haemolysis), tech-
nical examination of the device, chest radiogram and echocar-
diographic scans.
15.3 Driveline site management
Roughly half of the patients develop infection of the exit site
[71, 259, 363–376], making visual inspection of the wound at
every outpatient visit essential. Additionally, attention should
be paid to proper driveline positioning and the use of immobi-
lization devices. A photographic record and clinical scoring of
the driveline exit site are helpful in tracking its appearance over
time [71, 259, 363–376]. The incidence of infection after LT-
MCS implantation depends on patient-related risk factors [71,
259, 363–376].
Strict attention to driveline cleanliness should be ensured from
postoperative day 0 [363, 367, 369, 370, 374, 376]. Initially, the
dressing should be changed once daily, thus keeping the exit site
dry. The use of various anchoring devices to stabilize the drive-
line helps minimize the risk of trauma.
The patients should receive in-house training for driveline
care with family members before hospital discharge [363, 367,
369, 370, 374, 376]. After discharge, patients and/or their care-
givers should adhere to the proper aseptic technique. A drive-
line management pack for changing the dressing should be
given to the patient. Dressings should be changed by
patients and/or their family members and/or their caregivers
1–2 times per week according to the condition of the exit site
and the opinion of the VAD coordinator. Since patients with
LT-MCS are susceptible to infections, they should avoid situa-
tions that could place them at an increased risk [71, 259,
363–376].
15.4 Blood pressure management and heart failure
medication
Many patients still suffer from volume overload after LT-MCS
implantation [71, 377–384]. Therefore, most patients require diu-
retics after LVAD implantation. Diuretic doses must be reviewed
regularly to ensure relief of fluid overload and to avoid depletion
of intravascular volume, which could result in suction events,
pump alarms, arrhythmias and syncope.
Hypertension leads to increased afterload for the LVAD,
decreased LVAD flow and less effective left ventricular
unloading [71, 377–384]. Furthermore, there is a significant
association between Doppler-derived BP and a range of
adverse events including intracranial haemorrhage, throm-
boembolic events and progressive aortic insufficiency [71,
377–385].
With CF-LVADs, conventional measurement of BP is difficult.
Thus it is common practice to use a Doppler BP reading as the
mean systemic BP [382]. Newer oscillometric devices show
good correlation of systolic, diastolic and mean pressures in
patients with a CF-LVAD in comparison with intra-arterial pres-
sure [378].
As a therapy, angiotensin converting enzyme inhibitors or
angiotensin receptor blockers are the first-line drugs for post-
LT-MCS hypertension. Beta-blockers can be used in combina-
tion with angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers but caution should be exercised in
patients with marginal RV function. These agents may also be
useful for rate control in the setting of atrial or ventricular
arrhythmias (VAs). Calcium antagonists, especially the dihydro-
pyridines, can be used as a third option. Aldosterone antago-
nists should be used for their potassium-sparing and
antifibrotic effects.
15.5 Driving while on long-term mechanical circu-
latory support
Every country has its own regulations with regards to driving
with medical conditions, physician/provider responsibility in
reporting these conditions and physician/provider liability for
motor vehicle accidents that might occur as a result of these
patients driving. According to the literature [386–391], most
patients with an LT-MCS, NYHA functional class I–III and sta-
ble LT-MCS implantation qualify for private driving only and
are disqualified from commercial driving. A recent study shows
that a significant number of patients with LT-MCS continue to
drive a vehicle after implantation (72%), although the fre-
quency of driving dropped from nearly 80% driving daily to
52% [392].
15.6 Remote monitoring
Remote monitoring (RM) can aid in outpatient care and surveil-
lance of key parameters [71, 359–362]. RM provides a real-time
view and transmission of MCS data via secure wireless Internet-
based RM settings, thus potentially avoiding unnecessary hospi-
tal visits. The use of RM technology has only recently become
available for some LT-MCS systems. Future developments may
ease troubleshooting, provide more data from the patient and
the pump and eventually increase physician and patient
satisfaction.
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16. MYOCARDIAL RECOVERY
Myocardial recovery reportedly occurs in 5–10% of patients sup-
ported with CF assist devices, with higher recovery rates after lon-
ger support periods [9, 401]. Myocardial recovery is most likely to
occur in patients with dilative cardiomyopathy, myocarditis and
peripartum cardiomyopathy [393]. Younger patient age and
shorter duration of disease are predictors for myocardial recovery
[393]. Myocardial recovery, however, is unlikely in patients with
ischaemic cardiomyopathy. Different pharmacological therapies to
promote myocardial recovery have been proposed. Clearly, con-
tinuation and optimization of medical HF therapy and neurohu-
moral blockage are indicated in potential recovery candidates [71,
398, 402]. Certain subtypes of myocarditis and peripartum cardio-
myopathy also respond to medical treatment [403, 404]. Various
protocols to identify recovery candidates suitable for weaning
from LT-MCS have been proposed [393, 405].
16.1 Evidence review
All patients with non-ischaemic cardiomyopathy should be treated
as potential bridge-to-recovery candidates. Despite having the
potential effect of myocardial hypertrophy, the addition of the
beta-2 adrenergic agonist clenbuterol to standard HF therapy has
not been shown to be effective in promoting recovery. At the time
of LT-MCS implantation, potential myocardial recovery and device
weaning should be anticipated [71]. Significant heart valve diseases
that will not improve after LT-MCS implantation should be
addressed, and the prevention of adhesions that facilitate device
explantation should be considered [71]. Myocardial tissue that is
typically retrieved during apical coring should undergo histological
processing to identify treatable forms of myocarditis and assess
the possibility of myocardial recovery.
To identify myocardial recovery, a standardized screening
protocol should be used [393]. Accordingly, patients should
undergo routine echocardiographic screening during outpatient
visits at regular intervals. Specifically, ventricular function, shape
and dimensions should be assessed in a quantitative manner
[393]. In the setting of sinus rhythm and complete ventricular
remodelling (left ventricular end-diastolic diameter <_55 mm; left
ventricular ejection fraction >_45%), patients should be evaluated
with echocardiography at reduced pump speed for weaning eli-
gibility. If the findings are favourable and sustained, the patients
may progress to invasive testing [393], which may include
right heart catheterization with the pump speed reduced to the
lowest possible level for 15 min. Some centres have stopped
using the LVAD and balloon-occluded the outflow graft
[406, 407]. Thresholds for device explantation are cardiac index
>2.6 l/min/m2, pulmonary artery wedge pressure (mean)
Recommendations for outpatient care
Recommendation Class Level References
Mechanical circulatory support programme management
Management of outpatients with mechanical circulatory support therapy by a dedicated and specialized
multidisciplinary team is recommended. I B
[25, 37, 71,
137, 284,
354–360]
Successfully discharging a patient with mechanical circulatory support
Patient and caregiver education/training regarding device management, anticoagulation monitoring and driveline care is
recommended. I B
[25, 37, 71,
137, 284,
354–360]
Blood pressure management
In patients with continuous-flow mechanical circulatory support, a mean systemic blood pressure goal of <_85 mmHg
is recommended.
I B [71,
377–384]
Driveline dressing management
It is recommended that driveline wound monitoring, dressing and immobilization are performed frequently by
a trained person.
I C [71, 259,
363–376]
Driveline dressing should be changed by patients with mechanical circulatory support and/or their family
members and/or their caregivers only if all of them are well-trained.
I C [71, 259,
363–376]
Heart failure medication after implantation of a left ventricular assist device
Heart failure medication (diuretic agents, angiotensin converting enzyme inhibitor or angiotensin receptor blocker,
beta-blockers and mineralocorticoid receptor antagonists) should be considered during mechanical circulatory support. IIa C
[71,
377–384,
393–400]
Driving with a ventricular assist device
Evaluation and approval of driving ability by a mechanical circulatory support physician are recommended. I C [386–391]
Remote monitoring
Remote monitoring technology as a supplement to, rather than a substitute for, routine clinical visits for follow-
up of patients with long-term mechanical circulatory support may be considered.
IIb C [71,
359–362]
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<16 mmHg, right atrial pressure (mean) <10 mmHg [393, 406].
Adequate anticoagulation must be ensured.
Different strategies for LT-MCS explant have been described.
Depending on the individual patient’s situation and surgical pref-
erence, isolated removal of the pump and driveline or complete
device explantation might be appropriate [408]. In patients in
critical condition or patients with a high surgical risk (e.g. frailty),
ligation of the outflow graft through the subxyphoidal approach
or coiling in the catheterization laboratory with cutting of the
driveline below the skin without pump explantation might be
advisable (decommissioning) [409]. However, this technique
necessitates lifelong anticoagulation because the inflow cannula
remains in the ventricle. Complete system explantation should
be the standard approach for patients with device infection
[408].
After LT-MCS explant for myocardial recovery, patients should
receive lifelong treatment by HF specialists to target medical
therapy and identify recurrence of HF.
17. PUMP THROMBOSIS AND OTHER LATE
ADVERSE EVENTS
Despite improvements in the technical design of LT-MCS devices
and the clinical management of patients on LT-MCS, late compli-
cations commonly result in hospital admissions.
Late complications of LT-MCS, either ascribed to the pump
itself or to the interactions between the pump and the patient,
are classified as follows:
1. Complications intrinsic to the pump
a. Driveline
b. Pump malfunction
c. Outflow graft occlusion
2. Complications related to pump-patient interface
a. Pump thrombosis
b. GI bleeding
c. Cerebral vascular accident (CVA) (intracranial
haemorrhage, stroke)
d. Arrhythmia
17.1 Complications intrinsic to the pump
Background and description of the evidence. A total of
13% of device failures are caused by internal pump failure,
whereas over 60% are caused by the failure of batteries, the
controller and the peripheral cable [416]. Damage to the drive-
line that interferes with the operation of the pump is a rare, but
life-threatening complication. It is often caused by fracture due
to accidental mechanical impact. Continuous stress on the
cable due to growing body size with weight gain is a risk factor.
Moreover, accidental pulling of the cable by dropping the con-
troller bag or by patient falls risks cable damage [417].
Intentional cutting or disconnection of the driveline from the
controller has also been described [418]. Treatment of the
majority of lead fractures is a simple repair. If the damaged
driveline cannot not be repaired, it could require pump explant
or exchange, high-urgency HTx, or it could result in patient
death.
Pump malfunction is mainly a consequence of pump throm-
bosis, but technical failure of the broader system components,
including the controller, the batteries and the connectors does
occur. Technical failure of pulsatile pneumatically driven assist
devices has a higher incidence than that of CF-LVADs. Briefly,
stoppage of a TAH pump due to membrane rupture is a fatal
event; Berlin Heart EXCOR allows substitution of the failing exter-
nal component but not restarting of the pump in case of a pump
stop.
17.2 Complications related to pump-patient
interface
Background and description of the evidence. Thrombosis
may involve different parts of the MCS, any of which requires
specific treatment. Blood flow may be disturbed at different lev-
els of the LVAD system, such as obstruction of the inflow cannula
by ingested thrombus (prepump thrombosis), thrombus trapped
between the impeller and the housing (intrapump thrombosis)
and kinking or stenosis of the outflow graft (post-pump throm-
bosis). Outflow graft occlusion may be due to stenosis, thrombo-
sis or torsion and may lead to gradual reductions in flow and
eventual flow cessation with consequent HF symptoms or death
[419, 420].
Diagnosis encompasses clinical signs, pump parameters, labo-
ratory analyses and imaging. Usually, patients with pump throm-
bus present with various degrees of circulatory compromise and
Recommendations for the evaluation of myocardial recovery
Recommendations Class Level References
Pathological evaluation of myo-
cardial tissue obtained during
apical coring to identify treatable
aetiologies of heart failure is
recommended.
I C
[410, 411]
In patients with LT-MCS with
non-ischaemic cardiomyopathy,
optimized medical heart failure
therapy to promote myocardial
recovery is recommended.
I C
[405]
Adding a selective beta-2 adre-
nergic agonist to conventional
HF therapy is not recommended.
III B
Routine screening of patients
with LT-MCS with non-ischaemic
cardiomyopathy for myocardial
recovery by echocardiography,
including the ramp test, is
recommended.
I B
[397, 412]
Before explantation, invasive
haemodynamic examination of
patients with LT-MCS is
recommended.
I B
[398]
Cardiopulmonary exercise test-
ing may be considered prior to
the decision about LT-MCS
explantation.
IIb C
[413]
Screening for recurrence of heart
failure after LT-MCS explantation
is recommended.
I C
[414, 415]
LT-MCS: long-term mechanical circulatory support.
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pump alarms. Log-file analysis of the pump can distinguish
between different kinds of blood flow obstructions. The major
discriminant is power consumption: High power consumption is
a sign of intrapump thrombosis because of the high level of
energy needed to produce the same amount of flow in the pres-
ence of material-altering rotor movements. Low power con-
sumption translates into low flow alarms for any CF-LVAD.
Software is required to analyse the log-files downloaded from
the pump, including data concerning the pattern of the pump’s
power consumption and blood flow throughout the time of
symptom onset.
The most common clinical sign of intrapump thrombosis is
haemolysis. Haemodynamic instability and new-onset HF are
signs of pre- and post-pump thrombosis. Neurological events,
any pump flow abnormalities or any other thromboembolic
complications should be investigated.
Diagnostic tests for blood flow obstruction across the system
are ramp-test echocardiography [421, 422], computed tomo-
graphic scans and angiography. Echocardiography can be easily
combined with clinical and invasive parameters to evaluate the
performance of the LT-MCS device. Echocardiography is appro-
priate for testing the function of the pump, especially during
changes in pump speed in conjunction with haemodynamic
monitoring. An enlarged LV and opening of the aortic valve, in
combination with wide arterial pulse pressure, is suggestive of
blood-flow obstruction, even if the console is showing high
power consumption and flow. Echocardiography permits a
second-level in-depth analysis: measurement of the peak contin-
uous wave Doppler velocity of the LVAD outflow tract (normal
value for HeartMate II <2.7 m/s, <3.4 m/s for HeartWare ventric-
ular assist device (HVAD)) and the ramp test. Standard echocar-
diographic measurements for ramp studies have been published
for HeartMate II and HVAD: Blunted reduction of the left ventric-
ular end-diastolic diameter in response to an increase in pump
speed indicates an obstruction of flow through the device [421,
423]. A computed tomography scan with contrast is a valuable
tool for the visualization of the LV, inflow cannula and outflow
graft.
The definitive treatment of prepump thrombosis is surgical
pump exchange, although medical therapy (thrombolysis, gly-
coprotein inhibitors, unfractionated heparin) may be applied in
select cases [424]. Intrapump thrombosis should be treated with
lysis, with pump exchange or an urgent transplant if possible
[424–426]. Post-pump thrombosis can be treated with stenting
of the outflow graft [427]. Cases of kinking or twisting of the
outflow graft should be surgically corrected with untwisting of
the graft or pump exchange, because stenting is not useful
[420]. The recommendations are presented regarding
HeartMate II (Abbott, Lake Bluff, IL, USA), HeartWare HVAD
(Medtronic, Minneapolis, MN, USA) and HeartMate 3 (Abbott);
no data are reported for the Jarvik Flowmaker (Jarvik Heart Inc.,
New York, NY, USA), HeartAssist 5 (ReliantHeart Inc., Houston,
TX, USA) and Berlin Heart INCOR (Berlin Heart GmbH, Berlin,
Germany), or other devices. The reported incidence of pump
thrombosis is substantially lower for HeartMate 3 compared to
HeartMate II [2a] and supposedly the HeartWare HVAD,
although a prospective head-to-head comparison of the
HeartMate 3 and the HeartWare HVAD has not yet been
performed.
17.3 Gastrointestinal bleeding
Background. GI bleeding is the most common cause of hos-
pital readmission [428] and is observed early and late after
implantation. Reported incidences range between 5% and 34%.
Description of the evidence. The incidence of GI bleeding is
comparable between patients supported with different CF-
LVADs. Upper and lower GI endoscopies are the mainstay of ini-
tial investigations. Angiography and radionuclide imaging are
best suited for acute overt GI bleeding. Capsule endoscopy may
play a role in the diagnosis of obscure GI bleeding, usually from
the small bowel. Diagnosis and concomitant treatment are possi-
ble once the bleeding source is identified. Despite this, no active
bleeding site is identified in 30–50% of the cases [344, 429], and
it is often then assumed that the site of the bleeding is the small
intestine, where arterio-venous malformations are difficult to
identify and treat. The primary treatment goal is to stabilize the
patient; blood transfusions may be required. Anticoagulation
therapy is often interrupted until bleeding is resolved. Recurrent
GI bleeding warrants complete withdrawal of antiplatelet therapy
and setting a lower target INR, acknowledging the possible
increased risk of thromboembolic complications. There are posi-
tive reports of the use of octreotide and thalidomide in treating
occult and recurrent GI bleeding [430, 431]. However, these
drugs are not commonly used in some European countries and
there is limited long-term experience. Discontinuation of antith-
rombotic and antiplatelet therapy poses a potential prothrom-
botic risk that has to be balanced against the risk of recurrent
bleeding episodes [432].
17.4 Cerebral vascular accidents, intracranial
haemorrhages and strokes
Background. Thromboembolic complications are the clinical
consequences of inadequate haemocompatibility of currently
implanted LVADs, a phenomenon of unbalanced interactions
between the patient and the pump at different levels that leads
to haemorrhagic or ischaemic complications. Ischaemic stroke is
more common than intracerebral haemorrhage, but the latter is
more likely to be disabling or fatal.
Description of the evidence. CVAs are described for all
types of devices, and the reported incidences with modern devi-
ces remain high [145]. Overall incidence ranges from 6.7% to
29.7% (0.07 to more than 0.26 events per patient year). BP man-
agement is of primary importance: mean arterial pressure higher
than 90 mmHg is associated with a risk of stroke during CF-
LVAD support [146, 433]. Doppler BP measurement is the gold
standard, and it reflects systolic BP. Antiplatelet and antithrom-
botic therapies are crucial as prophylaxis against CVA: Use of
aspirin and strict anticoagulation monitoring are protective for
CVA.
The clinical management, diagnostic procedures and treat-
ment of CVA in patients with LT-MCS follow standard clinical
practice. Systemic thrombolysis is not recommended for
patients on LVAD due to the unacceptably high risk of bleeding.
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Instead endovascular interventions for acute ischaemic stroke
are warranted. Evidence from large trials suggests that lowering
BP decreased the incidence of stroke [146, 433]. Strict outpatient
management of BP is effective, considering that the risk of
stroke is shown to increase from 9 to 12 months post implant
[377, 434].
17.5 Arrhythmia
Background. Arrhythmias are frequent during LT-MCS and a
common cause of hospitalization. Ventricular and atrial arrhyth-
mias are often a manifestation of the underlying disease and fre-
quently present preoperatively. Several precipitating factors
contribute to early postoperative arrhythmia [435].
Description of the evidence. The burden of VA in LT-MCS
recipients is high; preoperative VA is the major predictor of
late postoperative VA. VA is reasonably tolerated by many
patients supported by LT-MCS with a low risk of immediate hae-
modynamic collapse [436]. The role of implantable cardioverter
defibrillators (ICDs) for primary prevention of sudden cardiac
death is unclear in patients supported by LT-MCS [84, 437].
Definitive data are not available: The largest retrospective study
included mostly pulsatile devices, and the conclusions are not
directly translatable to CF-LVAD [438]. For a subgroup of patients
who present with a history of refractory VAs, aggressive antiar-
rhythmic therapy and catheter ablation are indicated.
Atrial fibrillation is also common in patients with LT-MCS.
The effect on outcome and risk of thromboembolism is rele-
vant. Pharmacological rhythm control strategy is widely
accepted; other procedures (catheter ablation, left appendage
closure) have limited evidence. Pharmacological treatment is
indicated, and catheter ablation may be attempted in cases of
sustained or recurrent VA. In patients with an ICD implanted
prior to LT-MCS implantation, ventricular tachycardia therapy
should be active to prevent adverse sequelae of right ventricu-
lar dysfunction. However, ICD settings should be very conserva-
tive. Less evidence exists for primary prevention ICD in patients
without arrhythmia at the time of LVAD implantation. It might
be considered not to replace a depleted ICD battery in the
absence of VAs. ICD implantation is indicated for patients with
LT-MCS who develop postoperative VA with haemodynamic
deterioration.
Recommendations for pump thrombosis and other late adverse events
Recommendation Class Level References
Device malfunction
It is recommended that out-patient management encompass regular evaluation and inspection of the technical
parameters and all components of the external part of the device and their connections.
I C [416]
It is recommended that in cases of pump malfunction with clinical symptoms, the patient is assisted by
emergency medical service and referred to the implanting centre.
I C [417, 418]
Surveillance by abdominal radiogram to regularly assess internal components of the driveline may be
considered.
IIb C
In case of damage to the external parts of the driveline, splice repair of the wires in the operating room by
technical personnel, with a surgery team on standby, should be considered.
IIa C [439]
In-hospital evaluation is recommended for pump alarms signalling pump malfunction. I C
Pump thrombosis
In the case of a clinical thrombotic event, pump evaluation for device thrombosis is recommended. I C [422, 440]
Evaluation of the presence of pump thrombosis is recommended if flow alarms are present. I C [422, 440]
In the case of a flow obstruction, technical, clinical and diagnostic investigations of the outflow graft, pump
body and inflow cannula are recommended.
I C [422, 440]
Routine monitoring of lactate dehydrogenase and plasma free haemoglobin levels during follow-up is
recommended.
I C [441]
In the case of pump thrombosis of a HeartWare HVAD, device exchange should be considered. IIa C [424, 426]
In the case of pump thrombosis of a HeartWare HVAD, thrombolysis may be considered. IIb C [424, 426]
In the case of pump thrombosis of a HeartMate II, device exchange or a high-urgency heart transplant
(if possible) should be considered.
IIa C [424]
In a scenario of prepump (inflow graft) thrombosis, a backwash with carotid artery protection may be
considered.
IIb C [442]
In a scenario of post-pump (outflow graft) thrombosis, stenting should be considered. IIa C [422, 427,
443–446]
Continued
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18. AORTIC INSUFFICIENCY AND LATE RIGHT
HEART FAILURE
18.1 Background
Under LVAD support, de novo aortic insufficiency can develop.
The incidence varies in different publications from 10% [454]
to 53% [384]. Recirculating blood will lead to systemic hypoperfu-
sion of the patient. Additionally, incomplete unloading of the LV
may lead to pulmonary artery hypertension compromising the RV
function. Factors contributing to AR are fusion of the commissures
and degenerative changes of the cusps caused by persistent aortic
valve closure [455]. The diagnosis and the grade of regurgitation
can be confirmed by echocardiography.
18.2 Evidence review
Factors that influenced AR development and progression were
older age, persistent aortic valve closure, duration of LVAD sup-
port and female gender [456]. Treatment options include HTx,
bioprosthetic valve replacement, patch closure or valve repairs.
Transcatheter procedures have been shown to be effective for
patients in whom the risk of reoperation is prohibitive
[456–461].
Events of bleeding during LT-MCS
For a major bleeding event, temporary discontinuation of anticoagulation therapy is recommended. I C
For a critical clinical bleeding episode or if the international normalized ratio is >4, anticoagulation reversal is
recommended.
I C
If gastrointestinal bleeding is recurrent, discontinuation of platelet inhibitors should be considered. IIa C [428]
Evaluation of other causative factors that might influence the risk of gastrointestinal bleeding should be
considered.
IIa C [35, 117,
447–449]
In cases of occult recurrent bleeding despite the use of the above measures, octreotide or thalidomide may be
considered.
IIb C [430, 431]
Prevention and treatment of cerebrovascular accidents
A target mean arterial pressure <85 mmHg to reduce the risk of stroke is recommended. I B [377, 433,
434]
Computed tomography angiography is recommended for vascular imaging and endovascular treatment of
ischaemic stroke.
I A [450]
In cases of acute neurological deficit, emergent neuroimaging with computed tomographic scans is
recommended.
I A [450]
Reversal of coagulopathy with prothrombin complex concentrates or transfusions with fresh frozen plasma and
platelets is recommended for treatment of haemorrhagic stroke.
I A [451, 452]
Cardiac arrhythmias
In patients with long-term mechanical circulatory support who develop postoperative ventricular arrhythmia
with haemodynamic compromise, ICD implantation is recommended.
I C [438]
To prevent adverse sequelae of right ventricular dysfunction, continuation of ICD therapy should be
considered.
IIa C [435]
Prophylactic ICD implantation in patients without arrhythmias at the time of long-term mechanical circulatory
support implantation is not recommended.
III C [437, 438,
453]
ICD: implantable cardioverter defibrillator; LT-MCS: long-term mechanical circulatory support.
Recommendations for aortic insufficiency
Recommendations Class Level References
Diagnosis
Echocardiography for routine follow-up of aortic valve function is recommended. I C [460, 462]
The ramp test to diagnose aortic insufficiency should be considered. IIa C [463]
Treatment of moderate aortic insufficiency
Variation in pump speed settings to reduce aortic insufficiency should be considered. IIa B [68]
A heart transplant is recommended. I C
Open valve replacement or closure of an insufficient aortic valve is not recommended. III C
Continued
Recommendations for pump thrombosis and other late adverse events (Continued)
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18.3 Late right heart failure
Currently there is no established definition of late onset right ventric-
ular failure (LORVF). Although in 2 studies LORVF was defined as the
need for inotropic support or RVAD implantation starting 14 days
after surgery, another study defined LORVF as a readmission requir-
ing medical or surgical intervention [177, 468, 469].
18.4 Evidence review
In a large analysis of the INTERMACS database including 10 909
adult patients with primary LVAD support, the incidence of
LORVF (>14 days) was 6.4% [468].
In a retrospective single-centre study including 336 patients,
the incidence of LORVF was 11%. In these patients, diabetes mel-
litus, a body mass index >29 and blood urea nitrogen level
>41 mg/dl were significant predictors of LORVF [469].
Diagnostic investigations of LORVF should include echocar-
diography and invasive haemodynamic measurements with a
pulmonary artery catheter.
19. INFECTION
Infection remains a major source of morbidity and mortality in
patients with MCS despite significant progress in the develop-
ment of more durable VADs and advances in surgical techniques
over the last decade [25, 176]. The most recent INTERMACS
report showed that infection was still the fourth most common
cause of death within 1 year after implant [25]. The International
Society of Heart and Lung Transplantation recognized the impor-
tance of clearly defining infection in this unique population and
commissioned an international working group of experts to
develop definitions of infection in patients with MCS that were
published in 2011 [363]. Hence, these international definitions
are recommended for defining infection in Europe and are part
of this European consensus document.
19.1 Evidence for preventing infection in
preimplantation of mechanical circulatory support
Nosocomial bloodstream infection (BSI) has been reported as a
major source of morbidity and mortality in patients with MCS
[472]. In general the risk of infection associated with catheters
depends on type, location and duration in situ [473]. A recent
study from the International Society of Heart and Lung
Transplantation IMACS Registry, to which the EUROMACS
Registry contributes, showed that early-onset BSI was associated
with a significantly increased 24-month mortality rate and that
85% of these BSIs were not device related. There is an opportu-
nity for infection prevention practices to decrease the BSI event
rate in the intensive care unit and post-surgical settings, which
may affect the 24-month survival rate [474].
Catheter-associated urinary tract infection is the most com-
mon nosocomial infection and is preventable by limiting the
number of days of catheterization. As with indwelling catheters,
a general proactive approach in patients with MCS of changing
or reducing the duration of the catheters where possible to
reduce the risk of infection is recommended as per other inten-
sive care unit and post-surgical patients [475].
Interventional closure of the aortic valve may be considered. IIb C [458, 461,
464]
Transcatheter aortic valve replacement should be considered. IIa C [461, 465,
466]
Treatment of severe aortic insufficiency
Reduction in pump speed settings to reduce aortic insufficiency may be considered. IIb C [68]
High-urgent listing for a heart transplant is recommended if the patient is a transplant candidate. I C
Open valve replacement or closure of the insufficient aortic valve may be considered. IIb C [457, 467]
Interventional closure of the aortic valve may be considered. IIb C [458, 461,
464]
Transcatheter aortic valve replacement should be considered. IIa C [461, 465,
466]
Recommendations for late right heart failure
Recommendations Class Level References
Diagnosis
Routine follow-up echocardiog-
raphy for assessment of right
heart function is recommended.
I C
Invasive haemodynamic meas-
urements should be considered.
IIa C [470]
Treatment
Initial treatment for right heart
failure with diuretics is
recommended.
I C
Medical lowering of pulmonary
resistance may be considered.
IIb C [471]
High-urgent listing for a heart
transplant is recommended if the
patient is a transplant candidate.
I C
Secondary right ventricular assist
device implantation may be
considered.
IIb C
Recommendations for aortic insufficiency (Continued)
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19.2 Evidence for antimicrobial prophylaxis
perioperatively
In earlier studies, antimicrobial prophylaxis was broad spectrum
and given for a prolonged duration. Two published multicentre
surveys reported a wide variation in the different types of antimi-
crobial prophylaxis used in MCS implant surgery [476, 477].
More recently, MCS centres follow more general cardiac surgery
prophylaxis guidelines and do not include broad spectrum
gram-negative or fungal coverage. Cardiac surgery prophylaxis
guidelines usually recommend a cephalosporin (cefazolin or
cefuroxime) for 24–48 h, which can provide sufficient gram-
positive and gram-negative coverage [26, 478–481]. Routine anti-
fungal prophylaxis is not recommended [26].
19.3 Evidence for managing infection in patients
with mechanical circulatory support
Whenever clinically feasible, infection should be excluded or
appropriately treated before MCS implantation. In candidates for
MCS before implantation, evaluation of suspected infection is no
different from that in other patients and should be guided by
clinical signs and symptoms. In patients with unexplained fever
and/or leucocytosis, evaluation should include blood cultures,
urinalysis, urine culture and chest radiogram, with additional
imaging as needed until a diagnosis is established and the source
has been treated and cleared. In all MCS candidates with sus-
pected or proven infection, expert infection consultation is advis-
able. MCS candidates with BSI should be treated with targeted
antimicrobial therapy [363].
For an active infection, there is insufficient evidence to define
a minimum duration of antimicrobial therapy before proceed-
ing to MCS implantation [26]. However, delaying MCS implan-
tation is recommended where feasible until the following
general goals are met: control of the source (e.g. incision and
drainage of abscess, removal of infected catheter or tooth
extraction for dental abscess); blood culture results have
become negative after appropriate antibiotic treatment com-
menced; and illness and sepsis are resolved. Candidates for
MCS with other infections (e.g. pneumonia, urinary tract infec-
tion) should be treated with appropriate antimicrobial therapy
until resolution. Expert infection consultation should be sought
in all cases of infection preimplantation and throughout the
perioperative period.
19.4 Evidence for assessing a patient for
postoperative infection after implantation of
mechanical circulatory support
The initial evaluation should include a careful history and review
of symptoms. Physical examination of surgical wounds, driveline
exit site and review of the LT-MCS device function are essential
because early detection and treatment of a localized process
may prevent progression to more serious VAD infections [26,
363].
In case of driveline exit site infection, the treatment includes
increased frequency of dressing change, topical antiseptics and
prolonged or lifelong antibiotics (suppressive treatment). In case
of ascending driveline infection, surgical revision may be an
option.
Recommendations for prevention and treatment of infections preimplant and postimplant
Recommendations Class Level References
Infection prevention prior to LT-MCS implant
If time and clinical status permit, removal or exchange of all central venous catheters, pulmonary vein catheters
and urine catheter prior to LT-MCS device implantation is recommended.
I C [474,
482–484]
If time and clinical status permit, a dental assessment and therapy if required prior to LT-MCS device
implantation, are recommended.
I C [485]
A nasal and groin screen for methicillin-resistant Staphylococcus aureus and, if positive, treatment with topical
antibiotics prior to LT-MCS device implantation, are recommended.
I C [486, 487]
Antibiotic prophylaxis
Preoperative antimicrobial prophylaxis targeted at Staphylococcus sp. and methicillin-resistant S. aureus (in
patients with positive test results) is recommended.
I C [478–480]
The inclusion of antifungal treatment in routine preoperative antimicrobial prophylaxis is not recommended. III C [488, 489]
It is recommended that antibiotic prophylaxis be administered within 60 min of the first incision, remain in the
therapeutic range throughout its use and not be extended beyond 24 h after surgery.
I C [479, 490]
Managing active infection preimplant
In patients with active infections prior to LT-MCS device implantation, antibiotic therapy as directed by an
infectious disease expert is recommended.
I C [363]
Continued
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Infective endocarditis treatment preimplant
Documented clearance (negative blood culture results) of patients who have had bacteraemia prior to LT-MCS
device implantation is recommended.
I C
In patients with bacteraemia, antimicrobial therapy for at least 7 days prior to implantation of a mechanical
circulatory support device is recommended.
I C
In patients with bloodstream infections not related to infective endocarditis, removal of sources (if known) and
antimicrobial treatment are recommended.
I C
LT-MCS implantation in patients with untreated acute infective endocarditis with active bacteraemia is not
recommended.
III C
Preventing infection postimplant
It is recommended that the velour part of the driveline not exit the body. I C [259]
Stabilization of the driveline immediately after the device is implanted and continuing throughout the duration
of support is recommended.
I C [491]
A dressing change protocol initiated immediately postoperatively is recommended. I B [491, 492]
Secondary antibiotic prophylaxis for the prevention of infectious events during routine procedures and dental
work due to the risk of bacteraemia should be considered.
IIa C [71, 493,
494]
Evaluation of patients with mechanical circulatory support with a suspected infection
In all patients, a complete blood count, chest radiographic images and blood cultures are recommended. I C [363]
It is recommended to draw at least 3 sets of blood cultures over 24 h, with at least 1 culture from any indwelling
central venous catheter.
I C [363]
For those with a suspected pump cannula or driveline infection, obtaining a sample for gram stain, the KOH test
and routine bacterial and fungal cultures are recommended.
I C [363]
When clinically indicated, an aspirate from other potential sources, as dictated by presenting symptoms and
examination, is recommended.
I C [363]
Directed radiographic studies based on presenting symptoms and examination are recommended. I C [363]
Erythrocyte sedimentation rate or serial C-reactive protein should be considered. IIa C [363]
Routine computed tomography of the chest, abdomen and pelvis is not recommended. III C [363]
Leucocyte radiolabelled scintigraphy may be considered to identify deep infections but by itself lacks
anatomical specificity.
IIb C [495]
Combining single positron emission tomography/computed tomography scans with radiolabelled leucocytes
has increased the sensitivity for detection of infection and retained the specificity for anatomical location of the
MCS infection; it can also identify distal foci if infected emboli are present and should be considered.
IIa C
[496, 497]
Treatment of patients with mechanical circulatory support with a suspected infection of the driveline exit site or the driveline itself
A full evaluation as outlined above should be performed in all patients prior to treatment before commencing
antimicrobial treatment even if only superficial infection is suspected.
I C [363]
In patients with a superficial driveline exit site infection but without a BSI or systemic illness, it is recommended
that antibiotic therapy be deferred until culture results are known.
I C [71, 498,
499]
In patients with clinical signs of driveline exit site infection but with negative culture results, initiation of empiri-
cal oral antibiotic therapy and evaluation based on clinical response are recommended.
I C
In the presence of systemic illness and/or sepsis, initiation of empirical intravenous antibacterial therapy always
covering Staphylococcus, Pseudomonas and Enterobacteriaceae species, also taking local institutional epidemiol-
ogy and colonization (e.g. methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci) into
consideration, is recommended.
I C
Rifampicin should usually be avoided due to its significant impact on the international normalized ratio, but it
may be considered in rare cases.
IIb C [500]
It is recommended that the duration of antimicrobial treatment be guided by the clinical response, type of
infection, pathogen(s), transplant status and the opinion of an infectious disease expert.
I C
It is recommended that the treatment of a superficial infection without an associated BSI last at least 2 weeks. I C
For deep infections, treatment for at least 6 weeks, depending on the pathogen, time to clearance of the BSI, the
clinical response and the expert opinion of an infection disease expert, are recommended.
I C [26]
Continued
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20. END-OF-LIFE CARE
20.1 Introduction
Optimal care of patients with LT-MCS, especially those in whom
it is a destination therapy, has to include comprehensive end-of-
life (EOL) considerations. When life-prolonging therapy can be
expected to cause more suffering than benefit, palliative care
(PC) should focus on quality of life and an easy death in accord-
ance with the patient’s wishes.
Taking care of patients with LT-MCS as a destination therapy
can be more difficult than taking care of HTx candidates or HTx
patients [501–504]. Factors that can complicate advanced HF
management such as ageing-related comorbidities, end-organ
damage, cognitive impairment, frailty and limited social support
are compounded by risk of MCS failure and MCS-related com-
plications such as bleeding, infection and stroke. As a result, LT-
MCS is associated with repeated hospitalizations and a high rate
of caregiver burnout. The unpredictable course of advanced HF,
differences among LT-MCS devices and a limited evidence base
can further complicate shared decision-making, preparedness
planning and EOL care [503].
Successful PC requires a multidisciplinary approach with fluid
communication between the patient and caregivers on the one
hand, and between primary care services, the LT-MCS team and
PC specialists on the other [9, 71, 505, 506].
20.2 Review
For best EOL care, PC should begin before implantation of the
MCS device and continue throughout the duration of support,
especially for patients with increasing comorbidities [502]. The
main goals of PC for patients with LT-MCS are management of
symptoms, psychosocial issues and spiritual concerns. Therefore,
although communication with patients with advanced HF is
complex due to the highly unpredictable course of the disease,
among other things, there should ideally be a discussion with the
patient and caregivers about expectations, goals and EOL prefer-
ences during the evaluation of patients for destination therapy
LT-MCS. This discussion should lead to a comprehensive EOL
plan, focusing on conditions for withdrawal of MCS or related
medications, such as anticoagulation, being drawn up preopera-
tively and made available to all relevant parties [502, 504]. An
advance health care directive, also known as a living will, includ-
ing designation of a proxy decision maker for when the patient is
unable to make his or her own decisions, can be a great help
[507]. However, the plan should be re-evaluated whenever nec-
essary, since the patient’s acceptance of aggressive treatments
may change. Life-prolonging support may be discontinued with
the patient in the hospital, in a hospice for terminal patients or
at home. However, it should be pointed out that hospice care
prior to withdrawal may be problematic, since many hospice
staff lack experience and training with MCS therapies [502].
20.3 Symptom management
These patients often experience pain, which can be of multifac-
torial origin but frequently affects skeletal muscle and which can
be aggravated by the presence of the LT-MCS device. For pain
management, opioids have advantages over non-steroidal anti-
inflammatory drugs, since the latter affect renal function and vol-
ume status and increase the risk of GI bleeding. Mood disorders
such as anxiety and depression are very common as well, the
treatment of which, whether pharmacological or otherwise, may
require referral to a mental health specialist. In such cases there
can be a risk of suicide, because the patient has direct access to
the life-supporting device [502]. Other frequent symptoms that
must be addressed include anorexia, constipation and insomnia.
Single positron emission tomography/computed tomography combined with radiolabelled leucocytes for the
detection of location of infection and infected emboli should be considered.
IIa C [496, 497]
Leucocyte radiolabelled scintigraphy for identification of deep infection may be considered. IIb C [495]
If the infection is not eradicated despite debridement and 6 weeks of systemic intravenous antibiotic treatment,
specific surgical treatment of the infections should be considered, including driveline relocation, pump
exchange, prolonged treatment of the ventricular assist device, wrapping driveline with omentum and a heart
transplant.
IIa C
Lifelong antibiotic treatment for complicated S. aureus infection should be considered unless there is an option
to remove the device.
IIa C
Treatment of patients with mechanical circulatory support with a suspected infection of the pump
In all patients with mechanical circulatory support, a full evaluation for any suspected infection as outlined
above should be performed before commencing antimicrobial treatment.
I C [26, 363]
In the case of a persistent bloodstream infection, pump seeding or endovascular infection should be suspected. It is
recommended that intravenous antimicrobial therapy be initiated after microbiological samples have been taken.
I C
For infection in patients with mechanical circulatory support at the time of device exchange or heart transplant,
it is recommended that antimicrobial therapy be continued for at least 6 weeks, depending on the pathogen
and the clinical course, to minimize the risk of relapse.
I C
[26]
After failure of eradication of infection with debridement and 6 weeks of systemic intravenous antibiotic
treatment, specific surgical treatment of infections including pump exchange and a heart transplant should
be considered.
IIa C
LT-MCS: long-term mechanical circulatory support; BSI: bloodstream infection.
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20.4 Psychosocial and spiritual concerns
The single-centre Palliative Care in Heart Failure (PAL-HF) trial
showed that interdisciplinary PC of patients with advanced HF
afforded better quality of life and spiritual well-being, less anxiety
and lower risk of depression than conventional care [508].
20.5 Device-specific and physiological
considerations
The health professionals and/or caregivers who provide EOL
care must have specific training in defibrillator deactivation, the
minimization of VAD alarms and VAD deactivation and an
understanding of residual native heart function, which allows
estimation of how long the patient will survive following
deactivation.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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